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2. ABBREVIATIONS 
ADAM   a disintegrin and metalloprotease 
AP-1      activator protein 1 
AR     amphiregulin 
ATF     activating transcription factor 
BTC    betacellulin 
bZIP     basic region-leucine zipper 
CDK     cyclin-dependent kinase 
CREB    CRE-binding protein 
ECM     extracellular matrix 
EGF     epidermal growth factor 
EGF-R    EGF receptor 
EMT    epithelial–mesenchymal transition 
EP     epigen 
EPR     epiregulin 
ErbB     erythroblastic leukemia oncogene homolog; RTK 
Erk     extracellular signal-regulated protein kinase 
FCS     fetal calf serum 
FGF     fibroblast growth factor 
Fra      Fos-related antigen 
GPCR     G-protein coupled receptor 
Grb2     growth factor receptor-bound protein 2 
IGF-I    insulin like growth factor 
HB-EGF   heparin binding EGF 
HC     hydrocortisone 
IL    interleukin 
Ind     indomethasine 
JNK     c-Jun N-terminal kinase 
MAPK    mitogen-activated protein kinase 
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MAPKK   MAPK kinase 
MAPKKK   MAPKK kinase 
MEF     mouse embryonal fibroblast 
MMP    matrix metalloproteinase 
NF-kB    nuclear factor kB 
PDGF    platelet-derived growth factor 
PDGF-R   platelet-derived growth factor receptor 
PGE2    prostaglandin E2 
PI3K     phosphatidylinositol 3-kinase 
PKC     protein kinase C 
PLC     phospholipase C 
Ras     rat sarcoma viral oncogene homolog; GTPase 
RTK     receptor tyrosine kinase 
SH2     Src homology domain 2 
Shp1     SH2-containing tyrosine phosphatase 
Src     Rous sarcoma viral oncogene homolog; tyrosine kinase 
STAT    signal transducer and activator of transcription 
TGF-?    transforming growth factor ? 
TPA     12-O-tetradecanoyl-phorbol 13-acetate 
TRE     TPA response element 
VEGF    vascular endothelial growth factor 
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3. ABSTRACT 
Critical cellular decisions such as should the cell proliferate, migrate or differentiate, are 
regulated by stimulatory signals from the extracellular environment, like growth factors. 
These signals are transformed to cellular responses through their binding to specific receptors 
present at the surface of the recipient cell. 
The epidermal growth factor receptor (EGF-R/ErbB) pathway plays key roles in governing 
these signals to intracellular events and cell-to-cell communication. The EGF-R forms a 
signaling network that participates in the specification of cell fate and coordinates cell 
proliferation. Ligand binding triggers receptor dimerization leading to the recruitment of 
kinases and adaptor proteins. This step simultaneously initiates multiple signal transduction 
pathways, which result in activation of transcription factors and other target proteins, leading 
to  cellular  alterations.  It  is  known  that  mutations  of  EGF-R  or  in  the  components  of  these  
pathways, such as Ras and Raf, are commonly involved in human cancer. 
The four best characterized signaling pathways induced by EGF-R are the mitogen-activated 
protein kinase cascades (MAPKs), the lipid kinase phosphatidylinositol 3 kinase (PI3K), a 
group of transcription factors called Signal Transducers and Activator of Transcription 
(STAT), and the phospholipase C? (PLC?) pathway. The activation of each cascade 
culminates in kinase translocation to the nucleus to stimulate various transcription factors 
including activator protein 1 (AP-1). 
AP-1 family proteins are basic leucine zipper (bZIP) transcription factors that are implicated 
in the regulation of a variety of cellular processes including proliferation and survival, 
growth, differentiation, apoptosis, cell migration, and transformation. Therefore, the 
regulation of AP-1 activity is critical for the decision of cell fate and their deregulated 
expression is widely associated with many types of cancers, such as breast and prostate 
cancers. 
The aims of this study were to characterize the roles of EGF-R signaling during normal 
development and malignant growth in vitro and in vivo using different cell lines and tissue 
samples. We show here that EGF-R regulates cell proliferation but is also required for 
regulation of AP-1 target gene expression in fibroblasts in a MAP-kinase mediated manner. 
Furthermore, EGF-R signaling is essential for enterocyte proliferation and migration during 
intestinal maturation. EGF-R signaling network, especially PI3-K-Akt pathway mediated AP-
1 activity is involved in cellular survival in response to ionizing radiation. 
Taken together, these results elucidate the connection of EGF-R and AP-1 in various cellular 
contexts and show their importance in the regulation of cellular behaviour presenting new 
treatment cues for intestinal perforations and cancer therapy. 
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4. REVIEW OF THE LITERATURE 
4.1. Introduction 
Cancer is a genetic disease arising because of mutations in cancer-susceptibility genes, which 
can be modified by environmental factors. These cancer-associated mutations are either 
inherited or somatic and belong to one of the three classes: gatekeepers, caretakers, or 
landscapers. Of these, gatekeepers directly regulate growth and differentiation pathways in 
the cell. Gatekeeper genes consist of growth-promoting oncogenes and growth-constraining 
tumor-suppressor genes. In a normal cell, proto-oncogenes are counterbalanced by growth-
constraining tumor suppressor genes, but mutations that potentiate the activities of proto-
oncogenes create the oncogenes that force the growth of tumor cells. Caretakers in turn 
maintain the genomic integrity (prevent mutations) of the cell, and mutations of caretakers 
can lead to genetic instability. Defects in landscapers generate an abnormal stromal 
environment. At the tissue level, constancy in cell number results in tissue homeostasis, 
which reflects a highly regulated balance between the rates of cell proliferation and cell death. 
If this balance is shifted towards uncontrolled proliferation, cancer occurs [reviewed in (1)]. 
Actual tumor progression is a multistep process, which enables cells to evolve from benign 
group of cells to malignant tumors. One of the first steps is autocrine secretion of cancer cells 
(2, 3), which generally exhibits a reduced requirement for exogenously supplied growth 
factors to maintain a high rate of proliferation. At present, cancer progression has been 
suggested to depend on six essential characteristics identified as the hallmarks of cancer 
which include: 1) self-sufficiency in growth signals, 2) insensitivity to growth-inhibitory 
signals, 3) evasion of apoptosis, 4) limitless replicative potential, 5) sustained angiogenesis, 
and 6) tissue invasion and metastasis (4).  
Classically, basic cancer research has focused on either gain or loss-of-function mutations in 
oncogenes or tumor-suppressor genes, respectively. Many of the known proto-oncogenes 
code for proteins that are part of intracellular signaling network and therefore, carcinogenesis 
and  the  development  of  cancer  has  been  said  to  be  a  disease  of  the  signaling  system.  The  
intracellular signaling network is a highly complicated group of proteins transmitting signals 
and regulators that fine tune or inhibit this process, resulting in changes in cell proliferation, 
differentiation, cell migration, survival, and cellular metabolism. Signals received at the cell 
surface must be properly transmitted to critical targets within the cell to achieve the 
appropriate biological response. The process is often initiated by receptor tyrosine kinases 
(RTKs), which function as entry points for many extracellular cues, and play a critical role in 
recruiting the intracellular signaling cascades that orchestrate a particular response. The focus 
of this review is delimited to signaling events initiated by epidermal growth factor receptor 
(EGF-R) and its downstream target AP-1. 
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4.2 EGF receptor 
The EGF-R signaling has been widely studied since its discovery in late 1970´s (5). The EGF-
R was the first RTK cloned (6). Interstingly, the EGF-R cytoplasmic domain was found to be 
the human ortholog of the v-ErbB oncogene of the avian erythroblastosis virus, which lacks 
almost the entire extracellular region leading to constitutive signaling activity (7). This 
finding identified EGF-R as one of the first proto-oncogenes. During the 1990´s and 2000´s 
the complex kinase-signaling network underlining EGF-R has been revealed [reviewed in (8, 
9)]. Although this research has been very fruitful, it is now clear that a more complete 
understanding of key regulatory signaling pathways is required, since this receptor family and 
growth factor ligands play an essential role in the regulation of epithelial cell proliferation. 
The EGF-R family (also called HER/ErbB family) consists of four different tyrosine kinases 
(EGF-R, ErbB-2, ErbB-3, and ErbB-4) that are activated following binding of epidermal 
growth factor (EGF)-like growth factors (Table I and Figure 1B). A member of EGF-R family 
has an extracellular region that contains two ligand-binding domains (domains I and III), an 
extracellular juxtamembrane region, a single hydrophobic transmembrane domain, 
cytoplasmic tyrosine kinase-containing domain (except ErbB-3), and cytoplasmic tyrosine 
residues that serve as sites for receptor phosphorylation (Figure 1A) (10). The intracellular 
tyrosine kinase domains of Erb receptors are highly conserved, whereas their extracellular 
domains are not, suggesting that they can bind different ligands (See chapter 4.3 EGF-R 
ligands) (10-12). The EGF-R is expressed in almost all types of non-transformed cells, with 
the only exception of mature cells of the lymphohematopoietic system (13, 14). 
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Figure 1. The EGF-R protein structure and highlighted tyrosine kinase domain and C-
terminus with some of the most important phoshorylation sites (in bold) and interacting 
proteins (A). Dimerization of EGF-R homodimer after ligand binding (B). Modified from 
(15). 
 
4.3 EGF-R ligands 
The existence of seven EGF-R ligands [amphiregulin (AR), betacellulin (BTC), epidermal 
growth factor (EGF), epigen (EP), epiregulin (EPR), heparin binding EGF (HB-EGF), 
transforming growth factor (TGF-?)], and four ErbB receptors allows numerous 
combinatorial possibilities of signaling. This signaling diversity is based on several aspects. 
Firstly, the expression pattern of each ligand and their ability to induce not only EGF-R 
homodimers but also heterodimers are essential features. Secondly, EGF-R ligands BTC, HB-
EGF, and EPR are bivalent binding both EGF-R and ErbB4, which determines which receptor 
dimers are formed, influencing which signaling pathways are activated (16). Thirdly, each 
EGF-R ligand has a unique binding affinity, influencing signal strength and duration. 
Fourthly, the pH stability of the ligand–receptor interaction influences receptor trafficking. 
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For  example,  EGF-EGF-R  interaction  is  pH  resistant.  EGF-R  is  targeted  to  lysosomes,  
whereas TGF?-EGF-R interaction dissociates at endosomal pH, resulting in receptor 
recycling to the plasma membrane (17, 18). Therefore, TGF? often produces stronger or more 
prolonged effects than EGF (19). All these interactions play a role in signal potentiation. 
Thus, in response to EGF-R ligands the cells can proliferate, differentiate, survive, or move, 
indicating that EGF-R and its ligands have broad roles in different tissues during 
development, maintaining homeostasis, and regulating injury responses. 
EGF  is  a  prototypic  member  of  the  family  of  these  growth  factors.  It  is  a  single  chain  
polypeptide that was first isolated from mouse submaxillary glands (20), which serve as a 
source for circulating EGF. All EGF-R ligands are synthesized as transmembrane molecules 
that can release their extracellular domains containing the EGF-like motif through a 
specialized type of limited proteolysis, known as ectodomain shedding, which is regulated via 
protein kinase C (PKC) (21). This proteolytic processing by ADAMs (a disintegrin and 
metalloprotease) regulates the bioavailability of several EGF-R-ligands. ADAM10 is the main 
processor of EGF and BTC, and ADAM17 the main processor of EPR, EP, TGF-?, AR, and 
HB-EGF (22, 23).  
The neuregulins (NRGs) are additional ligands harboring an EGF-like domain. This domain 
binds to both the ErbB3- and ErbB4-receptor tyrosine kinases  (24) but also HB-EGF, BTC, 
and EP can bind to ErbB4 (25, 26).  
Soluble ErbB ligands generally act over short distances as autocrine or paracrine growth 
factors, activating EGF-R in the very EGF-R ligand-producing cell or in proximal cells, 
respectively. If the shedding is prevented the transmembrane forms of ligands also have the 
ability to activate EGF-R in adjacent cells in a juxtacrine fashion (27).  
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Table I. The ErbB receptors and their associated ligands. Modified from (28). 
EGF-R 
 
ErbB2 
 
ErbB3 
 
ErbB4 
 
Amphiregulin (AR) 
 
None 
known 
Neuregulin 1 
(NRG-1) 
Betacellulin (BTC) 
 
Betacellulin (BTC)  Neuregulin 2 
(NRG-2) 
Epigen (EP) 
 
Epidermal growth factor 
(EGF) 
  Heparin binding EGF 
(HB-EGF) 
Epigen (EP)   Neuregulin 1 (NRG-1) 
Epiregulin (EPR)   Neuregulin 2 (NRG-2) 
 
Heparin binding EGF 
(HB-EGF) 
  Neuregulin 3 (NRG-3) 
 
Transforming growth factor 
(TGF-?) 
  Neuregulin 4 (NRG-4) 
   Tomoregulin 
 
4.4 The EGF-R network during development 
In general, EGF-R ligands have important physiological roles in development as stimulators 
for epithelial tissue growth. However, they can also modify body composition and when 
overexpressed they have negative effects on growth of an individual. For example, 
overexpression of EGF, HB-EGF, or BTC leads to decreased body weight and retarded bone 
development in mice (29-32). The mechanism behind this might be that the EGF-R ligands 
stimulate proliferation and prevent differentiation of adipocytes and osteoblastic cells (33, 34). 
Furthermore, the EGF-R ligands are needed in the maturation of the gastrointestinal tract, and 
subsequent optimal nutrient uptake (35). They can also negatively regulate other growth 
factors such as insulin like growth factor (IGF-I) (32). In addition, they are chemoattractants 
for a number of different cell types and can contribute to cell adhesion, cell motility, and 
angiogenesis [reviewed in (36)]. 
During development, ErbB receptors and EGF-R ligands show distinct expression patterns 
that are organ- and developmental stage-specific. As EGF-R ligands act locally as autocrine 
or  paracrine  growth  factors,  the  availability  of  a  specific  ligand  is  an  essential  way  of  
controlling its functional consequence. 
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The role of an individual gene in development is currently studied by creating knockout (KO) 
animal models, usually mice, in which the desired target gene has been inactivated by 
homologous recombination. In general, mice with inactivated ErbB receptors develop 
multiorgan failure leading to embryonic or prenatal death, whereas inactivation of the ligands 
does not lead to lethality suggesting redundancy in their action (Table II). 
4.4.1 ErbB family knockout-mice 
Expression of the EGF-R already at a blastocyst stage indicates its importance during 
development (37). Indeed, EGF-R–/– mice suffer from impaired epithelial development of 
several organs, including the skin, lung, and gastrointestinal tract (38, 39). Together with 
placental defects they either lead to peri-implantation, embryonic, or postnatal lethality 
depending on genetic background of the EGF-R–/– mice strains (39-41). Furthermore, EGF-R 
signaling is necessary for normal craniofacial (42) and pancreatic development (38). The 
natural murine mutation of the EGF-R is called Waved-2. Waved-2 results from a point-
mutation in the tyrosine-kinase domain of the EGF-receptor unaffecting protein expression or 
ligand binding but leading to a reduced ligand-dependent autophosphorylation of EGF-R (43). 
It has a similar but not as severe phenotype as the EGF-R–/– mice. 
ErbB-2–/– mice have arrested oligodendrocyte development and myelin formation (44). In 
addition, mice have alterations in cardiac and neural structures that cause lethality at 
embryonic stage E10.5 (45, 46). Also, ErbB-3–/– mice die from severe degeneration of the 
nervous system at embryonic stage E13.5 (47, 48). Like ErbB-2–/– mice, the ErbB-4–/– mice 
die during mid-embryogenesis due to cardial and neural defects. The conditional nervous 
system-specific ErbB-4–/– mice also show altered motor and behavioral activities, suggesting 
a role for this receptor not only in neuronal development but also in neuronal function (49, 
50).  
To conclude, these phenotypes of ErbB receptor KO-mice reflect the importance of receptor 
heterodimerization and co-operation (See Table II). The heart and CNS are defective in all 
KO-mice implicating that ErbB receptors must co-operate during heart and CNS 
development. Interestingly, ErbB receptors also play essential roles in the adult organism. 
This  is  reflected  in  the  mammary  gland,  which  is  an  organ  that  undergoes  most  of  its  
proliferation and differentiation during pregnancy and lactation. All four ErbB receptors are 
expressed in the mammary gland in distinct patterns (51) and ErbB receptor KO-mice show 
defective mammary gland development at different stages.  
4.4.2 EGF-family knockout-mice 
EGF–/– mice have no clear phenotype. Even their growth rate is normal as compared to wild 
type littermates. EGF may also contribute to the mammary gland development and lactation 
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(52). EGF mRNA is expressed in the salivary gland, thyroid gland, mammary gland, and 
kidney, which serve as major sources of circulating EGF (53). 
TGF-?–/– mice have similar hair and eye defects as have been previously associated with the 
recessive mutation waved-1 (wa-1) (54). They also have abnormal skin architecture (55). In 
contrast, overexpression of TGF? results in hyperplasia and hyperkeratosis in the epidermis 
reminiscent to psoriasis (56).  
Heparin-binding epidermal growth factor (HB-EGF)–/– mice are viable and fertile but more 
than half of the HB-EGF–/– mice die during the first postnatal week and the survivors develop 
severe heart failure (57). HB-EGF is needed in blastocyst implantation (58) and wound 
healing (59). Furthermore, HB-EGF is reported to be a more potent stimulator of smooth 
muscle cell proliferation than EGF or TGF? (60). Moreover, HB-EGF also serves as receptor 
for diphtheria toxin (61).  
Amphiregulin–/– (AR) mice show no overt phenotype but have a distinct and essential role for 
AR in mammary ductal morphogenesis, supporting roles for EGF and TGF? in lactogenesis 
(52, 62). 
Betacellulin–/– (BTC) mice are viable and fertile and display no overt defects but the lifespan 
of HB-EGF–/–/BTC–/– mice is further reduced, apparently due to accelerated heart failure (63). 
However, BTC overexpressing mice have several pathological alterations (31). These include 
abnormalities in the eye, lung, and bone structure suggesting a unique role for BTC in EGF-R 
signaling.   
Epiregulin (EPR)–/– mice  do  not  manifest  any  abnormal  phenotype.  Unlike  other  EGF-R  
ligands, epiregulin shows dual biological activity; it stimulates proliferation of fibroblasts, 
hepatocytes, smooth muscle cells, and keratinocytes but inhibits growth of several tumor-
derived epithelial cell lines (64, 65). Epiregulin is mainly expressed on peripheral blood 
macrophages and the placenta (66). 
The newest EGF-R ligand is Epigen (EP) (25). No knockout mice have been produced yet but 
it is known that soluble EP is more mitogenic than EGF. EP expression is detectable in 
multiple organs of the mouse embryo (67).  
Overall, phenotypes of mice deficient in EGF ligands are mostly mild. This suggests 
redundancy between different ligands, which assures correct development and tissue 
homeostasis even if the expression of a single EGF-R ligand is lost. Even the triple KO-mice 
lacking EGF, AR, and TGF? are healthy and fertile, however, they are growth retarded and 
show impaired gastrointestinal tract development (35). EGF family members are also able to 
induce their own mRNA production and that of other family members in ligand-specific 
patterns, which suggests that they also have distinct, non-redundant functions (68). 
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Furthermore, overexpression studies revealed the importance of optimal levels of both milk-
derived and endogenous EGF-R ligands in regulating growth (discussed in the next chapters). 
Table II. Summary illustrating the phenotype of ErbB receptor or ligand inactivation. 
Target gene Phenotype outcome Reference 
EGF-R Impaired epithelial development in the skin, mammary 
gland, lung, pancreas and intestine 
(39) 
ErbB2 Impaired cardiac ventricular myocyte differentiation,  
impaired development of oligodendrocytes,  sensory 
ganglia and motor nerves in the CNS  
(44-46) 
ErbB3 Defective heart valves,  impaired differentiation in the 
cerebellum (CNS) 
(47, 48) 
ErbB4 Impaired cardiac ventricular myocyte differentiation,  
alterations in the hindbrain in the CNS 
(49, 50) 
EGF  (69) 
TGF? Abnormal skin structure (wavy hair),  eye anomalies (55) 
HB-EGF Enlarged cardiac valves and ventricular chambers, 
impaired wound healing 
(57, 59) 
Amphiregulin  Impaired mammary gland development (69) 
Betacellulin As above (63) 
Epiregulin As above, susceptibility to mucosal damage  (65) 
Epigen N/A N/A 
4.4.3 EGF-R in the intestine 
The epithelial lining of the gastrointestinal (GI) tract is constantly renewed. The homeostasis 
of the intestinal epithelium results from a highly regulated equilibrium between cell 
proliferation, migration, differentiation, and apoptosis (70, 71), which originates from a 
crosstalk between the epithelium and adjacent cell layers (72). 
The  epithelial  lining  consists  of  enterocytes,  which  are  polarized,  differentiated  epithelial  
cells. They possess a specialized apical surface facing the intestinal lumen as well as a 
laterobasal surface exposed to blood and subepithelial cells. EGF is secreted directly into the 
intestinal  lumen from several  different  cellular  sites  of  origin.  Indeed,  EGF is  known to  be  
present at physiological concentrations within the intestinal cavity but the localization of the 
EGF-R to the laterobasal membrane (73) or to the apical membrane (74) in enterocytes is still 
disputed. Also other EGF family members like TGF?, amphiregulin, heparin-binding EGF, 
and epiregulin are all expressed in the GI tract at some levels but for example in the foetal 
gut, TGF? is more widely distributed than EGF (75). 
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There  are  many  reports  showing  the  importance  of  the  EGF-R  signaling  system  in  the  GI  
tract.  During  development,  inactivation  of  the  EGF-R results  in  epithelial  immaturity  of  the  
GI tract. Similarly, as already mentioned, mice with triple KO mutations lacking AR, EGF, 
and TGF? show alterations in the GI tract (76). Moreover in a recent study, TGF? inhibits 
methotrexate-induced enterocyte apoptosis (77). 
Defective EGF-R signaling has also been implicated pathogenesis of necrotizing enterocolitis 
(NEC) (78), which is the most common gastrointestinal disease of prematurely born infants. 
The molecular mechanisms underlying EGF-mediated protection against NEC include the 
reduction of intestinal apoptosis (79) and an improvement of intestinal barrier function (80). 
EGF insufficiency or lack of EGF-R may play an important role in normal cell renewal and 
healing after cellular damage, since both EGF and TGF? promote cell proliferation and 
stimulate cell  migration. The natural  source of EGF and TGF? for newborn infants is milk, 
which contains high levels of these growth factors (81), which are also needed to ensure the 
optimal postnatal growth of neonates. 
Other  examples  of  the  role  of  the  EGF-R  signaling  system  in  the  GI  tract  include  
Helicobacteria pylori infection and Zollinger-Ellison Syndrome (ZES). H. pylori infection 
induces mucosal damage, which increases the expression of EGF peptide and EGF-R mRNA 
in the gastric mucosa (82), whereas patients with ZES typically have hypersecretion of acid 
and pepsin but also a significantly higher EGF concentration in saliva and gastric juice. This 
elevated content of salivary and gastric EGF in ZES patients may play a protective role in 
preventing the development of reflux esophagitis and gastric ulcer induced by gastric acid and 
pepsin (83). This type of protective but not mitogenic effect of EGF (and TGF?) reducing 
mucosal damage could result from their capability of inhibiting gastric acid secretion (84). 
It  has  been  reported  that  signaling  of  EGF-R  in  GI-tract  has  a  role  in  intestinal  cancer  
development (85), especially in colon cancer (86), in which EGF-R is over-expressed (87), 
but also in the pathogenesis of Ménétrier's disease (88). Furthermore, epiregulin–/–mice are 
highly susceptible to cancer-predisposing intestinal damage caused by oral administration of 
dextran sulfate sodium (89).  
4.4.4 EGF-R controlling the ECM and epithelial-mesenchymal interactions  
Adult mesenchyme consists of resident cells (such as fibroblasts, adipocytes, and osteoblasts) 
and wandering cells (such as macrophages and mast cells) embedded in the extracellular 
matrix  (ECM).  The  composition  of  the  ECM  is  tissue-specific  but  the  major  ECM  
components include collagens, proteoglycans, and a large number of non-collagenous 
glycoproteins and proteins (90). One type of the resident cells, the fibroblasts, synthesize and 
maintain ECM by secreting the precursors of the components of the ECM and by producing 
enzymes, such as matrix metalloproteinases (MMPs) that, e.g., degrade the epithelial 
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basement membrane and the ECM (MMPs are discussed in more detail in chapter 4.11). In 
such way fibroblasts provide a structural framework (stroma) for many tissues.  
During development the epithelial-mesenchymal interactions facilitate branching 
morphogenesis. It is well established that intact EGF-R signaling in fibroblasts is required for 
epithelial morphogenesis. EGF-R–/– mice have abnormal lung branching due to low 
expression of MT1-MMP (MMP-14) and reduction in active MMP-2 in the mesenchyme 
(91). In mammary ductal branching and morphogenesis, stromal EGF-R expressed by 
fibroblasts but also in this case by adipocytes in fat pads, is required for normal ductal 
development, which is activated by amphiregulin from mammary epithelial cells expressing 
ADAM17 (92, 93). In addition the growth of uterine, vaginal, and prostate organ requires 
EGF-R signaling from stroma (94, 95).  
An interesting example of an interplay between ECM and EGF-R function in fibroblasts is 
featured in Ehlers–Danlos syndrome patients (EDS), who have impaired wound healing due 
to mutations in genes coding for collagen type III or V (96, 97). Fibroblasts in an in vitro 
wounding assay derived from EDS patients show defective migration and regeneration repair 
(98). As a consequence of insufficient ECM anchorage, they also undergo growth arrest and 
anoikis (detachment induced cell death), which can be rescued by ???3 integrin-dependent 
EGF-R activation (99). In normal conditions, MMP3 plays a critical role in skin wound 
healing by mediating epithelial cell migration (100). In addition, the EGF-R ligands, 
especially HB-EGF, are essential in stimulating keratinocyte migration and proliferation in 
epithelialization during wound healing (59).  
The interaction between non-malignant stromal cells and tumor cells is known to be involved 
in cancer growth and progression. The trigger for tumor progression may come from signals 
in the stromal microenvironment (101, 102). The fibroblasts can modulate tumor cell 
migration and invasion through secretion of growth factors and cytokines in autocrine and 
paracrine fashion, and producing MMPs that modulate the ECM (103, 104). It has also been 
demonstrated that stromal fibroblasts might play a role in tumor associated angiogenesis by 
producing VEGF (105). As fibroblasts express all ErbB family members, the EGF-R system 
is an important tumor microenvironmental mediator regulating autocrine and paracrine 
circuits that contribute to enhanced tumor growth (28).  
4.5 Intracellular signaling pathways downstream of EGF-R 
Not only the impaired function of RTKs but also their signaling pathways have been linked to 
severe developmental defects, and various cancers (106). The major pathways downstream of 
EGF-R include MAPK pathways (Erk, JNK, p38), PI3-K-Akt pathway, STAT pathway, and 
PLC pathway, which are all illustrated in Figure 2 and discussed in the next chapters. 
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 In general, EGF-R network signaling controls cell fate during the development and adulthood 
of an organism. These include cellular events such as survival, proliferation, stress sensitivity, 
apoptosis, cell motility, gene expression, transformation, and differentiation. They also play a 
major role in oncogenesis and angiogenesis by regulating transcription factors with target 
genes including cell-cycle proteins like CDKs and ECM modulators like MMPs and 
angiogenetic factors like VEGFs. For example, Erk or PI3-K pathways are deregulated in 
approximately 30-70% of all human cancers. It is, therefore, extremely important to tightly 
control the ErbB signaling network at all levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A simplified diagram of the EGF-R signaling pathways. Each signaling cascade is 
shown in dash line box. EGF-R phoshorylation sites are marked with an asterix (*). Modified 
from (12, 107, 108).  
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4.5.1 ErbB receptor activation 
In the absence of ligand binding, the extracellular regions of monomeric ErbB receptors 
(EGF-R, ErbB-3, and ErbB-4) exist in equilibrium between the closed (inactive) and open 
(active) conformations, of which over 95% are in the closed conformation. Ligand binding to 
ErbB receptors stabilizes the ErbB extracellular region in the open conformation and induces 
the formation of receptor homo- and heterodimers.  This dimerization also activates the 
monomer kinase domains to form an asymmetric dimer resulting in phosphorylation on 
specific tyrosine residues within the cytoplasmic tail (Figure 1) (109, 110). The 
phosphorylated residues in the cytoplasmic tail and kinase domain serve as docking sites for a 
range of proteins, the recruitment of which leads to the activation of intracellular signaling 
pathways. 
Notably, there are specific differences between the ErbB receptors. The EGF-R has seven 
known ligands  and  can  form a  homodimer  or  a  heterodimer  with  all  the  other  ErbB family  
members. On the contrary, ErbB-2 is an orphan receptor but it is transactivated through 
heterodimerization with other ErbBs (111). ErbB-3 binds several types of neuregulins, but its 
tyrosine kinase domain is catalytically inactive (112). Therefore, the action of ErbB-3 and 
ErbB-2 are dependent upon combinatorial interactions with other members of the ErbB family 
and ErbB-2 is regarded as amplifier of ErbB signaling. ErbB-2 is the preferred 
heterodimerization partner for all other ErbBs (113). 
Ligand binding to EGF-R induces either homo- or heterodimerization, which then 
autophosphorylates many tyrosine residues within the C-terminus such as Tyr992, Tyr1045, 
Tyr1068, Tyr1086, Tyr1148, and Tyr1173 (Figure 1A). Alternatively also the Src non-
receptor kinase can phosphorylate Tyr845 and Tyr1101. Tyr845 phosphorylation stabilizes 
the activation loop, maintains the enzyme in an active state, and regulates signal transducer 
and activator of transcription 5 (STAT5) activity (114). Phospholipase C (PLC)-mediated 
signaling is stimulated by PLC-binding to a phosphorylated Tyr992 site. The phosphorylation 
of Tyr1045 creates a docking site for the ubiquitin ligase Cbl, which enables receptor 
ubiquitination and degradation (115). The phosphorylation of Tyr1068 and Tyr1086 
facilitates the binding of the SH2 domain of growth factor receptor-bound protein 2 (Grb2). 
This binding results in mitogen activated protein kinase (MAPK) activation through the Ras-
signaling pathway (116). SHP1 phosphatase can bind to the phosphorylated Tyr1173 domain, 
which leads to EGF-R dephosphorylation (117).  
4.5.1.1 Regulation of the ErbB receptors 
Receptor-mediated endocytosis is considered the major desensitization process of EGF-like 
growth factors, because it robustly removes ligands from the extracellular space and 
simultaneously targets cell surface receptors to intracellular degradation [reviewed in (118)]. 
Another suppressor is the ubiquitin ligase Cbl, which interacts with EGF-R directly and 
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indirectly through Grb2, promoting ubiquitination and degradation of EGF-R (119). Inhibitory 
signals promoted by crosstalk between RTKs (120), by protein phosphatases (121), and by 
negative feedback loops may affect signal specificity and biological outcome (122). 
4.5.2 MAPK signaling pathway 
Mammalian MAPKs can be activated by wide variety of stimuli, which include hormones 
(e.g., insulin), growth factors [e.g., PDGF, EGF and fibroblast growth factor (FGF)], 
inflammatory cytokines of tumor necrosis factor (TNF) family and environmental stresses 
such as radiation, osmotic shock, and ischemic injury (123, 124). These stimuli may act 
through  different  receptor  families  that  are  coupled  to  MAPK  pathways  (RTKs,  G  protein-
coupled receptors (GPCRs), cytokine receptors and Ser/Thr kinase receptors). Here only 
EGF-R related signaling is discussed. 
To date, six distinct groups of MAPKs have been characterized in mammals: extracellular 
regulated kinases (ERK1/2), Jun NH2 terminal kinases (JNK1/2/3), p38 (p38 ?/?/?/?), 
ERK7/8, ERK3/4, and ERK5. Major MAPK pathways are shown in Figure 3. Although each 
MAPK is unique, they share some common features, and have thus been grouped together in 
to one family. The central three-staged signaling module is standard for these pathways. It 
consists of a set of three evolutionarily conserved, sequentially acting kinases: a MAPK 
kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAPK. The MAPKKKs, also 
called MEKKs, are Ser/Thr kinases that are activated via phosphorylation and/or their 
interaction with small GTP proteins of Ras/Rho family in response to extracellular stimuli 
such as the activation of the EGF-R. MAPKKK activation leads to phosphorylation and 
activation of downstream MAPKKs, which are dual specificity kinases and can phosphorylate 
MAPKs on both threonine (Thr) and tyrosine (Tyr) residues on a conserved Thr-X-Tyr (X= 
any amino acid) motif. Once activated, MAPKs phosphorylate the target substrates on serine 
(Ser) or threonine (Thr) residues only if a proline (Pro) residue follows these amino acid 
residues [reviewed in (125)]. 
4.5.2.1 Erk signaling pathway 
The Erk cascade is activated by a large number of extracellular and intracellular stimuli. 
These include growth factors, serum, and phorbol esters by ligands of GPCRs, cytokines, 
osmotic stress, and microtubule disorganization (126). Erk1 and Erk2 are ubiquituosly 
expressed in all tissues. 
Erk1–/– mice have defective thymocyte maturation but are otherwise viable and fertile (127). 
In contrast, Erk2–/– mice embryos die before day E8.5 because of defects in trophoblast and 
placental development and in mesoderm differentiation (128-130). This suggests that Erk1 is 
nonessential and can be compensated by Erk2. 
 23 
The Erk pathway is activated after activation of EGF-R through the recruitment of Grb2 at the 
SH2-domain (Figure 3). The signal is transduced to small G proteins (e.g., Ras) (131) by 
phosphorylation that is mediated by son of sevenless (SOS). Activated Ras binds to 
MAPKKK such as Raf at the plasma membrane and Raf in turn triggers the phosphorylation 
of MAPKK called MEK1/2 (mitogen-activated protein kinase kinase 1/2) and Erk1/2. Most of 
the phosphorylated Erk1/2 translocates into the nucleus and activates various substrates. 
These include transcription factors such as c-Fos, kinases such as p90 ribosomal S6 kinases 
and MAPK-activated protein kinases (MAPKAPs), and cytoskeletal proteins such as 
neurofilaments and paxillin (132).  
4.5.2.2 JNK signaling pathway 
The JNK family was initially identified as ultraviolet (UV)-responsive group of protein 
kinases involved in the activation of transcription factor AP-1 component c-Jun by 
phosphorylating N-terminal Ser63 and Ser73 residues (133). Subsequently, it was shown that 
the JNKs are strongly activated in response to various types of stress, cytokines, growth factor 
deprivation, DNA damaging agents and, to lesser extent, by stimulation of some GPCRs, 
serum, and growth factors (Figure 3) (134-136). While JNK1 and 2 are ubiquitously 
expressed, JNK3 expression is restricted to the brain, heart, and testis. 
JNK1–/– and JNK2–/– mice are viable and fertile but have defective T cell differentiation (137, 
138). However, JNK1–/–JNK2–/– double knockout (KO) mice have neural tube defects 
resulting in embryonic lethality (139). JNK3–/– mice are also viable but KO-studies have 
revealed that JNK3 is a critical component of stress induced JNK signaling in brain and 
neuronal apoptosis (140, 141). 
It  is  not  entirely  clear  how  growth  factor  receptors,  for  example,  EGF-R,  activate  the  JNK  
family. One mechanism may be via Ras proto-oncogene and GTP-binding proteins of the Rho 
family, in particular CDC42 and RAC1. They activate at least 10 different MAPKKKs (i.e., 
MEKK1–4, MLK2 and -3, Tpl-2, DLK, TAO1 and 2, TAK1, and ASK1/2 (124)). They are 
specific for different stimuli, which allow the downstream activator MAPKKs called MKK4 
and MKK7 to respond to diverse range of external stimuli. TAK1 has been shown to be 
critical for JNK activation in response to inflammatory cytokines (IL-1, TNF-a, TGF-b, and 
lymphotoxin-b) and activation by Toll-like receptors (TLR-3, -4, and -9) (142, 143). MEKK3 
appears to be critical in response to activation by TLR-8 (144).  
Like ERK1/2, the JNKs may relocalize from the cytoplasm to the nucleus following 
stimulation  (145)  but  not  in  as  significant  proportions  as  Erk.  A  wide  range  of  nuclear  
proteins, predominantly transcription factors and nuclear hormone receptors, has been 
demonstrated to be substrates of JNK (124). JNK has been observed to have a central role in 
both extrinsic and intrinsic apoptotic pathways and depending on the cellular context it can be 
either anti- or pro-apoptotic. Many anti- and pro-apoptotic mitochondrial proteins, such as the 
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Bcl-2  family  proteins  (Bcl-2,  Bcl-xl,  Bad,  Bim,  and  Bax)  have  also  shown  to  be  targets  of  
JNK (146). 
4.5.2.3 p38 signaling pathway 
The same stimuli that activate JNKs also activate p38s. There are four known isoforms of 
p38, (i.e., ?/?/?/?). Among these p38? has been extensively studied. 
The p38?–/– mice die at E10.5 due to impaired placental development (147). However, studies 
using mice with conditional alleles of p38 have revealed an essential role for p38 in the lung 
and fetal hematopoietic development (148). Moreover, the p38?–/– mice are prone to cancer 
development in carcinogen- (148) or oncogene-induced cancer models (149), suggesting a 
tumor suppression function for p38? (150). 
Similarly to JNK pathway, Rho family GTPases appears to play an important role as upstream 
activators of the p38 MAPK pathway (Figure 3.). Several MKKKs have been reported to 
cause p38 activation; most of them are same with the JNK pathway. Furthermore, the p38 
group kinases are activated by MKK3 and MKK6, but also share some upstream kinases with 
JNK, namely MKK4 and MKK7 (151). 
The role of p38 MAPK signaling in cellular responses is diverse, depending on the cell type 
and stimulus. For example, p38 signaling can negatively regulate cell proliferation by 
modulating expression of EGF-R (149) or activating p53 (152), thereby activating apoptosis 
and  acting  as  a  tumor  suppressor.  This  type  of  regulation  also  involves  JNK  and  c-Jun,  as  
their activity is upregulated in p38?–/– cells and their inactivation can cause suppression of 
increased proliferation (148, 149). The ability of ionizing radiation to regulate p38 MAPK 
activity appears to be highly variable (153-155). 
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Figure 3. A simplified diagram showing mitogen- and stress-induced activation of mitogen-
activated protein kinase (MAPK) pathways. EGF-R phoshorylation site is marked with an 
asterix (*). Modified from (107, 108, 156). 
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Akt1–/– mice are small in size (161), indicating that Akt1 is involved in the control of growth 
and proliferation. Akt2–/– mice in turn have a diabetes-like syndrome (162), indicating that 
Akt2 regulates cellular metabolism. Similarly to Akt1, Akt3 is also involved in growth 
control, but considering its limited expression pattern, Akt3–/– mice manifest only a decreased 
brain size (163). 
EGF-R itself is a weak direct activator of PI3K, but can activate PI3-K by via the adaptor 
protein Grb2 and docking protein Gab1, or by heterodimerization with ErbB3 (164, 165) 
(Figure 2). PI3K phosphorylates PI 4,5-biphosphate (PIP2) to form PI 3,4,5-triphosphate 
(PIP3) in a reaction that can be reversed by the PIP3 phosphatase PTEN. PIP3, 
phosphoinositide-dependent kinase-1 (PDK1), and Akt form a complex at the plasma 
membrane and PDK1 phosphorylates Akt at its pleckstrin homology (PH) domain. With over 
100 substrates, phosphorylated Akt has multiple effects both in the cytoplasm and in the 
nucleus. These include the inhibition of pro-apoptotic factors, such as BAD (BCL2 antagonist 
of cell death), procaspase-9, and the Forkhead (FKHR) family of transcription factors 
(FOXO). Akt-mediated activation of mammalian target of rapamycin complex 1 (mTORC1) 
is also important in stimulating cell proliferation, and vascular endothelial growth factor 
(VEGF) and hypoxia inducible factor-? (HIF-?) are important in angiogenesis (166, 167). 
4.5.4 STAT signaling pathway 
The signal transducer and activator of transcription (STAT) family is comprised of seven 
proteins (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6). EGF-R 
phosphorylation can activate STAT1, STAT3, and STAT5s (Figure 2). EGF-R signals to 
STATs directly by binding to its SH2 domain but also through EGF-R-mediated activation of 
Src, upstream of STATs (168). 
The activated STAT proteins translocate into the nucleus and regulate gene expression crucial 
for cell survival, proliferation, transformation, and oncogenesis (169). 
4.5.5 PLC-PKC signaling pathway 
PLC (phospholipase C) binds through its SH2 domain to phosphorylated EGF-R tyrosine 
kinase to become active (Figure 2). Once activated, PLC hydrolyses phosphatidylinositol 4,5-
biphosphate to diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 mediates calcium 
release from intracellular stores, affecting a large number of Ca2+-dependent enzymes, 
whereas DAG is a cofactor for the activation of the serine/threonine kinase protein kinase-C 
(PKC). PKC has extensive homology to PKB (Akt1/2/3) within their kinase domains and are, 
therefore,  members  of  the  AGC  kinase  family  (other  kinases  are  PKA  and  PKG).  The  
activation of PKC results in cell-cycle progression, transformation, differentiation, or 
apoptosis depending on the cell context (170). 
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4.5.6 Signaling pathway regulation, specificity, and crosstalk 
Protein phosphorylation by kinases is regulated by reverse actions of the phosphatases 
(dephosphorylation), providing an important means of controlling protein activity. In general, 
because MAPK kinases are involved in cancer development as tumor promoters, their 
phosphatases can be considered as tumor suppressors. For example in a recent study, 
mitogen-activated protein kinase phosphatase-1 (MKP-1) is shown to inhibit invasion in 
human glioma cells (171). Likewise, inactiving mutation of the PTEN phosphatase on the 
PI3K-Akt signaling pathway is associated with multiple cancers such as glioblastoma and 
prostate. For example, PTEN is mutated in 50% of metastatic prostate cancers (172). 
Another mechanism that contributes to the specificity of MAPK cascades is the formation of 
multiprotein complexes via multidomain proteins called as scaffold proteins. These proteins 
bring together the components of a single pathway, and insulate the module from activation 
by irrelevant stimuli and negative regulators like phosphatases. They can also determine the 
localization of the cascade components and provide better stability to some components of the 
cascade. By doing so, scaffold proteins induce faster kinetics of activation, modify signaling 
duration and intensity, secure better interaction between distinct components, and modify the 
cross-talk with other pathways (173).  
An example of a negative-feedback loop modulator is the Sprouty2 protein in the MAPK 
cascade. Its expression is induced by activated Erk. Subsequentially, Sprouty2 binds through 
its conserved cysteine-rich domain to Ras or Raf resulting in inhibition of the phosphorylation 
and activation of Raf, and following activation of Erk. Recent study shows that this inhibitory 
effect is also regulated by another protein called Tesk1, which interacts with Sprouty2 to 
abrogate its inhibition of Erk phosphorylation (174). 
The crosstalk between distict pathways can be either inhibitory or stimulatory. For example, 
Akt can also block Erk signaling through inhibition of c-Raf [Raf1; (175)], but this crosstalk 
between Akt and Erk signaling is not ubiquitous and appears to occur only in specific 
settings. In addition to Erk, JNK and p38 have also been shown to be inhibited by Akt 
signaling. Akt can directly phosphorylate apoptosis signal-regulated kinase 1 (ASK1, also 
known as MAPKKK5), which is an upstream activating kinase within the JNK and p38 
pathways (176). This creates one possible balance switch between PI3K-Akt survival 
signaling and JNK/p38 apoptotic signaling. 
Other regulatory mechanisms include subcellular localization of proteins and post-
translational modifications such as acetylation, sumoylation, and ubiquitination, which seem 
to play an important role in transducing the signal by altering the protein stability, duration of 
activation, localization, or protein-protein association (125). 
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4.5.7 EGF-R transactivation  
RTK transactivation refers to a mechanism by which a ligand indirectly activates a RTK for 
which it does not serve as  a  direct  ligand.  Multiple  RTKs,  such  as  EGF-R,  platelet-derived 
growth factor receptor (PDGF-R), and c-Met, are potential targets of receptor transactivation 
by diverse ligand/receptor families (177-179). GPCRs and their ligands (such as thombin, 
angiotensin, lysophosphoatidic acid, and endothelin) represent one example of a receptor 
family that participates in EGF-R family transactivation (177, 180). For example, GPCR 
stimulation can lead to metalloproteinase dependent processing of EGF-like ligands, which in 
turn activate EGF-R (181). Janus tyrosine kinase pathway agonists, such as leptin, growth 
hormone, and  prolactin,  and  the  Frizzled  receptor  ligand  WNT  have  also been found to 
activate EGF-R-dependent cell signaling (182, 183). The binding of WNT ligand to its 
receptor Frizzled transactivates EGF-R. The mechanism seems to be similar to that described 
for GPCRs, as it is rapid and blocked by metalloproteinase inhibitors; however, the target 
ligand has not been identified. WNT- Frizzled-mediated transactivation has been observed in 
normal mammary cells (183) and in breast cancer cells. 
Cytoplasmic mechanisms of transactivation include a direct phosphorylation of EGF-R 
tyrosines by Jak2 or by non-RTKs, such as Src (184, 185). Direct transphosphorylation of 
kinase domain tyrosines can result from RTK heterodimerization such as PDGFR/EGF-R, c-
Met/EGF-R (178, 186).  
Radiation can also induce EGF-R activation. In this special type of activation the EGF-R is 
internalised into the nucleus and binds to the catalytic subunit of the DNA-PK, a key enzyme 
of DNA double strand break repair. Bound to the DNA, the EGF-R can act as a transcription 
factor or a co-factor of DNA repair (187-189). 
4.6 EGF-R in cancer 
Abnormalities in the expression and signaling pathways downstream of EGF-R family 
contribute to malignant transformation in human cancers, especially including those of the 
epithelial and neuronal origins. EGF-R is frequently overexpressed in the majority of human 
carcinomas (13, 190) but the frequency of this phenomenon varies among the different tumor 
types and tumor stage, overexpression being more common in the metastatic stage.  
Due to the high frequency of expression of individual ErbB receptor types in human 
carcinomas, co-expression of different receptors occurs in the majority of tumors. This 
phenomenon might be important for tumor pathogenesis, as some of the signaling pathways 
activated by these receptors differ, resulting in additive or synergistic effects (191). 
Particularly, overexpression of ErbB2 leads to EGF-R-ErbB2 heterodimerization with 
amplified signaling and increased proliferation, migration, and resistance to apoptosis (192). 
The redundancy of expression in human carcinomas is not limited to the ErbB receptors. In 
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fact, a number of studies have demonstrated that co-expression of different EGF-like peptides 
occurs in a majority of human carcinomas [reviewed in (193)]. Gene amplification, activating 
mutations as well as up-regulated autocrine loops by increased release of ligands (194), makes 
the  EGF-R  system  a  significant  component  potentially  associated  in  all  six  hallmarks  of  
cancer (4).  
4.6.1 EGF-R mutations 
Two main categories of EGF-R mutations have been identified: deletion of the extracellular 
domain and somatic mutations in the tyrosine kinase domain, both leading to increased 
signaling activity. For example, in non small cell lung cancer (NSCLC) almost 90% of all 
somatic mutations occur at two mutuational “hot spots” in the tyrosine kinase domain as 
either delEx19 and/or L858R (195). Other mutations include T790M and insertion mutations 
in exon 20 (196). An EGF-R deletion mutant called EGF-RvIII lacking  a  portion  of  the  
extracellular ligand binding domain (exons 2-7) is the most prevalent naturally occurring form 
of EGF-R mutation, and is found in most glioblastomas and medulloblastomas. In addition, 
expression of EGF-RvIII has been described to occur in breast, ovarian, and lung carcinomas 
(197).  
4.6.2 EGF-R expression in cancer 
Gene amplification of EGF-R has been demonstrated to occur in different tumor types and it 
is usually associated with overexpression of EGF-R protein. However, overexpression of 
EGF-R in the absence of gene amplification has also been described (13, 190). In 
glioblastoma multiforme (GBM), EGF-R gene amplification has been found in 37% to 58% 
of the tumors (198). The mutant EGF-RvIII accounts for more than 50% of the genomic 
alteration  of  EGF-R observed  in  GBM (199).  On average,  50% to  70% of  lung,  colon,  and  
breast carcinomas have been found to express EGF-R or ErbB-3. In contrast, ErbB-2 
expression is generally more restricted, with approximately 15% of human primary breast 
carcinomas expressing this receptor. The expression of ErbB-4 has been mainly investigated 
in breast carcinoma, where this receptor is overexpressed in approximately 50% of the tumors 
[reviewed in (190, 200)] but it has been recently demonstrated to occur in 22% of human 
primary colon carcinomas (201). In the clinic EGF-R has been associated with 
chemoresistance, disease progression, and poor survival (202). 
One example of cancers, in which EGF-R is likely to be clinically important, is prostate 
cancer. Prostate cancer is the most common cancer in men in Europe, with about 190 000 new 
cases (203) and about 80 000 deaths annually (204). The progression of advanced, metastatic 
androgen-independent prostate cancer is the final stage of this disease and constitutes the 
majority of mortality. 
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It is known that EGF-R expression increases during the progression of prostate cancer (205). 
Correlation  of  disease  progression  and  hormone-refractory  disease  suggests  that  EGF-R-
targeted drugs could be of therapeutic relevance in prostate cancer. Thus far, however the 
prognostic significance of EGF-R expression remains unclear, as reports on this issue are 
contradictory [reviewed in (206)]. In a recent study, EGF-R expression in prostate cancer was 
not found to be an independent prognostic variable according to univariate analysis (207). 
4.6.3 EGF-R downstream signaling 
Key downstream effectors of EGF-R include Ras and the MAPKKK Raf proto-oncogenes 
and protein tyrosine kinases like c-Src. They can all be mutationally activated and/or 
overexpressed in a wide variety of human cancers. As described in chapter 4.5, they are 
important signal transduction elements in many growth factor receptor signals for 
proliferation and transformation and if mutated and thereby activated they can significantly 
interfere with EGF-R targeted therapies (1, 108).  
4.6.4 EGF-R targeted therapies 
Since EGF-R pathways are commonly deregulated in human epithelial tumors, therapeutic 
agents directed against the EGF-R represent a promising and important group of biologically 
based treatment strategies. Next these EGF-R-directed therapies are discussed. 
First of all, the EGF-R targeted anticancer drugs are not curative in solid human tumors. 
However, when used alone, they can provide palliation and in combination with chemo- or 
radiotherapy they can significantly improve patient´s outcome. To date, EGF-R-directed 
therapies are approved for the treatment of colon, lung, head and neck, and pancreatic cancer 
(208). 
Two classes of well identified groups of EGF-R inhibitors are in clinical use: Monoclonal 
antibodies (cetuximab (Erbitux®) and panitumumab (Vectibix®)), which bind at the extra 
cellular part of the receptor and prevent binding of the natural ligands, and small molecular 
tyrosine kinase inhibitors (TKIs) (gefitinib (ZD1839, Iressa®); erlotinib (OSI 774, 
Tarceva®)), which inhibit phosphorylation of the intracellular tyrosine kinase by blocking the 
ATP binding site (Figure 4). Preclinical data indicate considerable heterogeneity in the tumor 
responses between TKIs and antibodies (209-211).  The phase III  trial  with radiotherapy and 
simultaneous treatment with cetuximab in patients with squamous-cell carcinoma of the head 
and neck (HNSCC) showed an improvement of local tumor control and survival (212). 
Likewise, cetuximab-chemotherapy (irinotecan) combination was shown to be significantly 
better than gefinitib or erlotinib alone in improving response rates and progression free 
survival of colon carcinoma patients (213). Furthermore, erlotinib in combination of 
chemotherapy improved response rates and survival in comparison to chemotherapy alone in 
pancreatic  cancer  (214).  In  contrast,  in  lung  cancer  patients,  a  phase  III  trial  failed  to  show 
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that gefinitib would be effective in improving survival (215). Likewise, gefitinib as 
monotherapy in patients with non-metastatic hormone refractory prostate cancer (HRPC) in a 
phase II trial showed no significant activity (216). Moreover, in a recent phase III study, the 
addition of cetuximab to chemotherapy and bevacizumab (antibody against VEGF) treatment 
in metastatic colorectal cancer resulted in a significantly shorter progression-free survival 
(217). In prostate cancer treatment radiotherapy is important treatment modality, however so 
far  no  results  of  the  clinical  trials  on  EGF-R  TKIs  in  combination  with  radiotherapy  are  
available. 
 
 
 
 
 
 
 
 
 
Figure 4. Different inhibition mechanisms targeted against EGF-R. Approved monoclonal 
antibodies as targeted against the extracellular domain to block ligand binding but also other 
strategies are under investigation (see info box). TKIs are targeted against ATP binding site in 
the kinase domain. ADCC; antibody dependent cell cytotoxicity, CDC; complement 
dependent cytotoxicity. Modified from (15). 
 
4.6.4.1 Mechanisms of resistance to anti-ErbB therapeutics 
There are several molecular explanations for the mechanisms of resistance to anti-ErbB 
therapeutics. One resistance mechanism is the activation of alternative tyrosine kinase 
pathways. One of the pathways contributing to the resistance of anti-EGF-R therapies is the 
Akt survival pathway, which is known to be activated by ErbB-3-dependent mechanism 
resulting from Met amplification (218). Another EGF-R-independent pathway is the IGFI-R 
pathway, which activates Akt after decreased expression of IGF binding protein-3 (IGFBP3) 
(219) . 
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The  ligand  independent  activation  of  the  pathways  downstream  of  EGF-R  is  another  
resistance mechanism. It has been demonstrated for the most commonly expressed mutation 
variant, EGF-RvIII (220). In addition, EGF-RvIII cannot bind the EGF-R-targeted 
monoclonal antibody cetuximab, and has been reported to be resistant to gefitinib (221). 
Mutations in the ATP-binding region in the kinase domain can also lead to impaired (222) or 
to a total blockade (T790M mutation) of TKI binding in NSCLC (223).  
Furthermore, the efficacy of EGF-R-therapies depends on additional mutations in the EGF-R-
dependent pathways. For example, tumor cells overexpressing EGF-R but having wild type 
K-Ras were effectively radiosensitized by the EGF-R-TK inhibitor BIB1382BS, whereas 
tumor cells presenting mutated K-Ras were not (210, 224). K-Ras mutated tumor cells were 
demonstrated to overproduce EGF-R ligands TGF? and amphiregulin, which in an autocrine 
manner selectively stimulated EGF-R-PI3K-Akt survival signaling (225). However, no 
correlation has been found between activated Akt and survival time in NSCLC patients 
treated with gefitinib in a randomised phase III trial (226). Other important resistance 
mechanisms  of  EGF-R  targeted  therapies  are  mutations  in  the  PTEN  phosphatase.  Loss  or  
mutation of PTEN might cause tumor-cell resistance to EGF-R therapeutics, because in cells 
with  low PTEN levels  activation  of  the  PI3K-Akt  pathway becomes  independent  of  EGF-R 
activation. The occurrence of PTEN mutation increases as prostate cancer develops towards 
the metastatic type (172). Loss of PTEN also enhances JNK activation and Akt and JNK 
activation are highly colocalized in human prostate cancer (227).   
4.7 AP-1 transcription factor 
When these above-mentioned signaling pathways are activated by ErbB receptors, their 
downstream targets are various transcription factors such as c-myc, STAT, and nuclear factor 
kB (NFkB). 
One major target of the EGF-R-MAPK cascades is transcription factor activator protein-1 
(AP-1). It is composed of dimers of various combinations of the Fos and Jun proteins (228) or 
closely related ATF and CREB proteins. The Fos family consists of four genes (c-Fos, FosB, 
Fra-1, and Fra-2), whereas the Jun family has three members (c-Jun, JunB, and JunD). Fos 
and  Jun  proteins  can  form heterodimers  with  Jun  family  proteins  and  Jun  proteins  can  also  
form homodimers (229, 230).  
4.7.1 Structure of AP-1 
A common feature of all AP-1 proteins is the bZIP domain, which is a basic DNA-binding 
domain combined with a leucine zipper region. The leucine zipper is responsible for 
dimerization, which is a requirement for DNA binding mediated by the basic domain (Figure 
5). The basic domain is mediating binding to a specific DNA sequence, TGAC/GTCA known 
as the TRE (TPA-responsive element) or AP-1 site (231), which is found in the promoter 
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region of many genes including those involved in cell growth and cell cycle control. Different 
AP-1 dimer combinations and the surrounding DNA sequence determine the affinity for a 
given TRE (229, 232, 233).  
The transactivation domain is responsible for mediating transcriptional activity. Within the 
transactivation domain c-Jun has two serines (Ser63 and 73) and two threonines (Thr91 and 
93), which are essential for its transcriptional activity (See chapter 4.7.3). Likewise, the c-Fos 
has two treonines (Thr325 and 331) and two serines (Ser362 and 374) (234). The individual 
Jun and Fos proteins have significantly different transactivation potentials. Jun, Fos, and FosB 
are considered strong transactivators; JunB, JunD, and Fra-2 have only weak transactivation 
potential and Fra-1 lacks the transactivation domain totally. The AP-1 proteins also have 
domains which act as docking sites for several kinases. These include DEF domain for Erk in 
c-Fos and delta domain for JNK in c-Jun. 
 
 
 
 
 
 
 
       
 
Basic region:      C-terminal transactivation 
responsible for DNA binding   domains of Fos   
 
Leucine zipper:    Delta-domain: 
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 Transactivation domain of Jun  DEF domain:    
       docking site for Erk  
     
Figure 5. Domain structures and phosphorylation sites of c-Jun and c-Fos proteins. Modified 
from (235).  
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4.7.2 AP-1 expression 
Each of the AP-1 proteins is differentially expressed and regulated, which means that every 
cell type has a complex mixture of AP-1 dimers. The proximal promoters of the AP-1 genes 
are conserved between different species and AP-1 can positively or negatively regulate its 
own transcription.  Even  if  most  of  the  AP-1  genes  are  inducible,  this  is  not  reflected  at  the  
protein level as such, because both posttranscriptional and posttranslational modifications can 
regulate AP-1 expression (228, 236). 
In adult mice c-Jun is expressed in many different cell types at low levels. It´s expression is 
enhanced in response to many stimuli including growth factors (for example EGF, NGF and 
FGF), UV irradiation, or cytokines. JunD in turn has high basal expression in many cell types 
(237). JunB expression is restricted to differentiating epidermal cells and endodermal gut 
epithelium (238) and it is inducible by growth factors.  
4.7.3 Transcriptional activity of AP-1 
Transcriptional activity and protein stability of the most studied AP-1 family member, c-Jun, 
is increased by JNK or Erk mediated phosphorylation of serines 63 and 73 (133, 239), 
whereas phosphorylation of threonines 91 and 93 may enhance c-Jun DNA binding ability 
(240). JNKs are the only MAPKs which can phosphorylate all four sites [reviewed in (241)]. 
Similarly, the stabilization and activation of c-Fos is mediated by the activity of Erks 
phosphorylating two c-Fos c-terminal sites (Ser362 and Ser374) (234). In addition, the Erks 
are involved in the induction of c-Fos expression via phosphorylating the transcription factor 
Elk-1/TCF, which activates the c-fos promoter (242). 
Similarly, other Fos, Jun and ATF proteins are regulated by phosphorylation giving rise to 
dimers with different transactivation properties [reviewed in (236, 243)]. Transcription 
cofactors (coactivators and corepressors) can also interact with AP-1 proteins and other 
transcription factors and the basal transcriptional machinery (including RNA polymerase II 
and basal transcription factors) (Figure 6). For example, c-Jun phosphorylation may potentiate 
its transcriptional activity through recruitment of CREB binding protein (CBP), which is 
proposed to connect the phosphorylated activation domains of coactivator CREB or c-Jun to 
the basal transcriptional machinery (244). Another transcriptional coactivator, DNA 
topoisomerase I (Topo I), was recently shown to interact with c-Jun affecting c-Jun mediated 
EGF-R expression and proliferation (245). Other cofactors include histone acetyltransferase 
(HAT) and deacetylases (HDAC) that control gene transcription through modification of 
chromatin structure. For example HDAC SRT1 binds to c-Jun and inhibits it´s transciptional 
activity (246). Furthermore, AP-1 activity can be down-regulated by sumoylation (247) and 
ubiquitin-dependent protein degradation (248). 
 35 
Altogether, the regulation of net AP-1 activity can be achieved through changes in the 
transcription of genes encoding AP-1 subunits, control of the stability of their mRNAs, post-
translational processing and turnover of pre-existing or newly synthesized AP-1 subunits, and 
specific interactions between AP-1 proteins and other transcription factors such as ETS (249). 
The  abundance  of  different  AP-1  members  within  a  given cell, as well as the cell lineage, 
differentiation stage, microenvironment, and type of stimulus have an impact on how AP-1 
modulates the decision of a cell to proliferate, differentiate, or die by apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Transcription of a specific gene involves the cooperative assembly of different gene-
specific transcription factors like AP-1, transcription cofactor complexes and the basal 
transcriptional machinery (BTM). Their activity is controlled by kinases and phosphatases 
and co-factors HAT (coactivator regulation) and HDACS (corepressor regulation). BTM, 
basal transcriptional machinery; HAT, histone acetyltransferase; HDAC, histone deacetylase; 
TRE, 12-O-tetradecanoylphorbol-13-acetate response elements. Modified from (250). 
4.8 AP-1 in development  
Studies in mice deficient in Jun or Fos expression have provided valuable information on 
their role in development and disease.  
The phenotypes of AP-1 knock-out (KO) mice are described in the following chapter. 
Interestingly, only the absence of JunB and Fra-1 gives rise to a similar phenotype whereas 
TRE 
Kinases/ 
Phosphatases 
Various cell-type specific 
stimuli, RTKs etc. 
DNA 
BTM 
AP-1 
proteins 
AP-1 
Dimer 
HAT/HDACS 
Co-factor 
Complexes 
Other 
Transcription 
Factors 
Nucleus 
 36 
inactivation of the other AP-1 members leads to distinct phenotypes, indicating specific and 
unique functions for each AP-1 subunit. However, c-Jun KO mice can be rescued with JunD. 
AP-1 members can also compensate each others function in vivo. For example during the 
development and differentiation of the immune system none of the c-Fos or c-Jun KO mice 
show altered B or T cell production or function regardless of in vitro data that have implicated 
AP-1 as a critical transcription factor of this system [reviewed by (251)]. 
4.8.1 Jun family knockout-mice 
Loss of c-Jun leads to embryonic lethality due to defects and abnormalities at the molecular 
level in the heart, aorta, and liver (252, 253). Loss of JunB also leads to embryonic lethality, 
because yolk sac vascularization is impaired (254). Mice lacking JunD are viable but mutant 
males show impaired spermatogenesis (237). 
4.8.2 Fos family knockout-mice 
Mice lacking c-Fos are viable and fertile but lack osteoclasts resulting in an osteopetrotic 
phenotype (255). In contrast, mice lacking FosB develop normally (256). Loss of Fra-1 leads 
to embryonic lethality due to defects in the placenta and the yolk sac (257), which has 
similarities compared to JunB–/– mice. The phenotype of mice lacking Fra-2 has not yet been 
reported. It is however known that Fra-2 controls osteoclast survival and size (258). 
4.9 AP-1 controlling cellular growth and apoptosis 
4.9.1 Proliferation 
The above mentioned studies using cells or mice either lacking or overexpressing single or 
multiple AP-1 components have demonstrated that AP-1 proteins have versatile functions in 
the regulation of cell proliferation, and have identified some AP-1 target genes, which directly 
link AP-1 expression to the cell cycle machinery. Control of cell proliferation by AP-1 seems 
to be mainly mediated by its ability to regulate the expression and function of cell-cycle 
regulators including cyclinD1 (259) and CDK inhibitory proteins such as p21Waf1/Cip1. 
Particularly, c-Jun is a negative regulator of p53 tumor suppressor and its target gene, the 
CDK inhibitor p21Waf1/Cip1, thus making c-Jun a positive regulator of cell proliferation, which 
is important in cancer development (260, 261). 
However, the effects of AP-1 are highly dependent on the cellular subtypes. For example, the 
tissue-specific inactivation of c-Jun in mice has highlighted that c-Jun is essential for 
regulation of cell cycle in fibroblasts, hepatocytes, and keratinocytes (262-264). In contrast, 
JunB and JunD are often considered to be negative regulators of cell proliferation. Other 
members of the AP-1 family c-Fos, FosB, and Fra-1 appear to be dispensable for cell cycle 
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progression, since fibroblasts and embryonic stem cells lacking these components have no 
proliferation defect (256, 257, 265-267). 
4.9.2 Apoptosis 
JNK phosphorylates c-Jun, which results in enhanced transcription of target genes involved in 
stress-induced apoptosis. Among the pro-apoptotic targets of c-Jun are the genes that encode 
FasL and TNF-?. c-Fos might negatively regulate FasL expression, since a transcriptional 
repressor element within the FasL promoter constitutively binds c-Fos but not c-Jun (268). 
Enhanced apoptosis in the absence of c-Jun is observed in keratinocytes and notochordal cells 
(264, 269). In contrast, in differentiated neuronal cells, c-Jun mediates JNK induced 
apoptosis, whereas in non-differentiated neuronal cells ATF-2, not c-Jun, is mediating the 
apoptotic signals (270). These studies reveal a critical, but cell type specific roles for c-Jun in 
survival signaling. Also other AP-1 members play important roles in regulation of pro-
apoptotic and anti-apoptotic target genes. For example, JunB downregulates anti-apoptotic 
Bcl-family proteins leading to increased apoptosis of myeloid cells (271).  
4.10 AP-1 in cancer 
AP-1 proteins are significant modulators of tumorigenesis; as they regulate the expression of 
critical target genes in all steps of tumorigenesis [oncogenic transformation, proliferation 
(EGF-R, cell cycle proteins), apoptosis (Bcl proteins), invasive growth (MMPs), and 
angiogenesis (VEGF) (reviewed in (272)]. In addition, AP-1 activity is maintained by 
mutated signaling proteins, such as EGF-R, Ras, and Raf or by various growth factors, whose 
expression are deregulated in cancer development. No mutations in jun or fos genes have been 
identified so far but a recent study showed jun oncogene amplification in highly aggressive 
sarcomas (273). In general, the expression of several AP-1 components is frequently 
upregulated in many cancers. 
The role of AP-1 in tumorigenesis is subunit and tissue dependent. For example, c-Jun is 
required for cellular transformation by activated Ras in fibroblasts in vitro since 
transformation is suppressed in fibroblasts lacking c-Jun or expressing a truncated, dominant-
negative form of c-Jun (274). c-Jun is also a positive regulator of proliferation (See also 4.9.1 
Proliferation), regulating cell cycle genes and p53 (261). Moreover, c-Jun and c-Fos can 
induce transition of tumor cells from an epithelial to a mesenchymal morphology known as 
the epithelial–mesenchymal transition (EMT) (275, 276). In  contrast,  ectopic  expression  of  
JunB or JunD in immortalized fibroblasts inhibits Ras-induced oncogenic transformation 
suggesting that these Jun proteins can act as anti-oncogenes (tumor suppressors) (277). 
At present, the role of AP-1 in malignant tumors in vivo is widely studied. In general, 
increased expression of AP-1 subunits has been observed during growth of malignant tumors 
but there is no regular pattern of AP-1 complexes that would serve as a marker for increased 
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invasion or malignancy. However, over-expression of c-Fos can contribute to development of 
osteosarcomas (278) and splenic marginal zone lymphomas (279). Also elevated Fra-1 
mRNA and protein have been detected in multiple tumors as well as transformed cell lines, 
including breast, colon, and lung (280) indicating that Fra-1 may have a role in cancerous 
transformation.  
AP-1 function in prostate cancer is still poorly understood. However, the high expression of 
IL-6, which functions as a growth and differentiation factor in hormone-refractory prostate 
cancer, is due to enhanced promoter activity resulting from combined activation of NFkB, 
JunD, and Fra-1 (281). A recent study reveals a role for AP-1 in prostate cancer progression, 
especially activated c-Jun as a marker of high-risk prostate cancer (282). Another study shows 
that c-Jun in stromal fibroblasts regulates production and paracrine signals of IGF-1 and 
stimulate epithelial proliferation in benign prostatic hyperplasia (283). 
4.11 Matrix metalloproteinases as AP-1 target genes 
Interaction of the cells with extracellular matrix (ECM) is critical for the normal development 
and function of organisms. Zinc-dependent endopeptidases called matrix metalloproteases 
(MMPs) are a major group of enzymes that regulate this cell-matrix composition and tissue 
modeling. Although, they are nowadays also considered as important regulators of signaling 
networks by modifing the activity of signaling molecules on the cell membrane or ECM 
[reviewed in (284)]. One example of such activity is discussed in chapter 4.11.2.  
In general, MMPs are synthesized by most cells but particularly fibroblasts and immediately 
secreted into the ECM as inactive precursors. Insufficient control of MMPs prevents normal 
cell migration, while excessive degradation results in loss of cell attachment to the ECM, as 
well as pathologic destruction of connective tissue, resulting in diseases such as arthritis, 
atherosclerosis, periodontitis, and cancer. Interestingly, MMP deficient mice have only mild 
phenotypes suggesting redundancy and many overlapping substrates [reviewed in (285)] and, 
moreover, that MMPs are required mainly for postnatal tissue development and tissue 
remodelling. Indeed, most MMPs are expressed at low levels under normal conditions in 
tissues but their expression is induced when remodeling of ECM is required. These situations 
normally include wound healing and inflammation [reviewed in (286)].  
4.11.1 Regulation of MMPs 
MMP expression is primarily regulated at the transcriptional level. Transcription factor AP-1 
is  one  of  the  major  regulators  of  growth  factor-inducible  MMP  expression.  These  MMPs  
include for example MMP1 (collagenase-1), -3 (stromelysin-1), and -9 (gelatinase B). 
Inducible MMP genes can be stimulated or repressed by growth factors and cytokines, which 
in many cases results in 20–50 fold changes in mRNA and protein levels. In contrast, the 
constitutively synthesized MMP2 (gelatinase A) is widely expressed by most cell types but 
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the MMP2 promoter does not have an AP-1 binding site (287). 
Interaction between AP-1 and the members of different transcription factors like ETS provide 
fine-tuning of the transcriptional regulation of MMP promoter activity. The ETS proteins 
usually  do  not  dimerize  and  bind  to  DNA  alone,  but  co-operate  with  AP-1,  for  which  they  
function as co-activators (249, 288). This type of a functional interplay between AP-1 and 
ETS factors in the regulation of MMP gene expression may modulate the response of MMP 
promoters. The activity of the transcription factors that control growth factor-responsive 
MMPs is phosphorylation-dependent and mediated by PKC and MAPK pathways (Erk, Jnk 
and p38), but cyclic adenosine monophosphate (cAMP) also plays a role in this regulation. 
(289-291).  
In addition to transcriptional control other regulatory levels are also involved. These include 
activation and inhibition of MMP activity, compartmentalization to specific membranes, the 
cysteine-switch mechanism and protein degradation (292). The important physiological 
activators of inactive precursor MMPs are plasmin and urokinase type plasminogen activator 
(uPA) and tissue-type plasminogen activator (tPA) (293). All active forms of matrix 
metalloproteinases are inhibited by tissue inhibitors of metalloproteinases, TIMPs (TIMP-1, 
TIMP-2, TIMP-3 and TIMP-4) (294) but also inhibitors of metalloproteinases (IMPs). 
4.11.2 EGF-R and MMP interactions 
Although the identity of all metalloprotease(s) involved in ectodomain shedding of pro-ErbB 
ligands stimulated by various reagents is not known, both MMP and ADAM family of 
metalloproteases are implicated to have a role in it (See 4.3 EGF-R ligands). The ADAM 
family, particularly ADAM10 and ADAM17, has been shown to mediate extracellular 
cleavage of several EGF-R/ErbB ligand precursors, whereas MMP-3 and MMP-7 cleave and 
produce an active form of HB-EGF in vitro (295). Other signaling molecules, such as VEGF, 
IGF and FGF, which are located extracellularly in the ECM, are also processed by MMPs 
leading to their activation and to possible EGF-R transactivation by their respective receptors. 
These and numerous other in vitro and in vivo studies have established that MMPs participate 
in the development of tumors as well as in invasion, metastasis and angiogenesis [reviewed in 
(296)]. For example, in primary breast tumors, there is a correlation between high EGF-R 
activity and high ADAM17 levels (297). Similar observation has been hade in gastrointestinal 
stromal tumors (GIST), in which ADAM17 is upregulated and coexpressed with EGF-R and 
EGF-R ligands HB-EGF and amphiregulin (298).  
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5. AIMS OF THE STUDY 
The purpose of this study was to investigate the function of EGF-R and its downstream 
signaling during development and pathological events in normal and cancer cell-line models 
and in fetal intestine, especially focusing on the MAPK/AP-1 signaling pathway but also 
covering the PI3K/Akt pathway. The functions of these EGF-R regulated pathways needed to 
be understood in further detail to confirm and clarify their roles in events mentioned in the 
following specific aims. Despite preciding studies, the exact mechanisms of these signaling 
pathways in these settings have remained unclear, therefore, the specific aims were: 
1) To identify whether EGF-R and AP-1 pathways interact in the fibroblasts 
2) To determine the signaling network of EGF-R in the fetal enterocytes 
3) To explore the role of AP-1 signaling in prostate cancer cell proliferation and 
radioresistance 
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6. MATERIALS AND METHODS 
6.1 Materials 
The materials used in this study are summarized below.  
 
Antibodies Manufacturer/Provider/Reference Study 
Actin 
Alpha-Tubulin 
Akt 
c-Fos 
c-Jun 
COX-2 
Cyclin B 
Cyclin D1 
EGF-R 
ERK1/2 
Fra1 
Fra2 
JNK 
JunB 
JunD 
p21 
p38 
phospho Akt (ser476) 
phospho EGF-R 
phospho c-Jun (ser73) 
phospho Erk 
phospho JNK 
phospho p38 
 
Conjugates: 
HRP-goat anti-rabbit 
HRP-rabbit anti-mouse 
TexasRed-mouse anti-rabbit 
 
Santa Cruz 
Sigma 
Cell Signaling Technologies 
Santa Cruz 
Santa Cruz 
Cayman Chemical 
NeoMarkers 
NeoMarkers 
Sigma 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Santa Cruz 
Cell Signaling Technologies 
Cell Signaling Technologies 
Biosource International 
Cell Signaling Technologies 
Promega 
Promega 
Cell Signaling Technologies 
 
 
Jackson Laboratories 
Jackson Laboratories 
Jackson Laboratories 
 
III 
II 
II, III 
I, III 
I, III 
II 
II 
II 
I, II, III 
I, II, III 
III 
III 
I 
III 
III 
II 
I, II, III 
II, III 
I, II, III 
I 
I, II, III 
I, II 
I, II 
 
 
I, II, III 
I, II, III 
II 
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Expression vectors Manufacturer/Provider/Reference Study 
adMEKca 
adTAM67 
AP-1 Luc 
Col Luc 
Col Luc mut 
 
(299) (Foschi M, et al.) 
(300) (Auer KL, et al.) 
Clontech 
(301) (Treier M, et al.) 
(301) (Treier M, et al.) 
I 
I 
III 
I 
I 
 
6.2 Methods 
The methods used in this study are summarized below.  
6.2.1 Cell culture and treatments 
All cells were cultured in a humidified 5% CO2 atmosphere at 37?C. 
DU145 (III) 
DU145 (HTB-81, prostate carcinoma cell-line) was purchased from the American Type 
Culture Collection (ATCC) and cultured in RPMI 1640 medium supplemented with 10% fetal 
calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin, and 100 ?g/mL streptomycin.  
FHs74Int cells (II) 
FHs74Int (CCL-241, Fetal human small intestine cell-line) was purchased from the ATCC 
and cultured in Dulbecco´s Modified Eagle´s Medium (DMEM) supplemented with 10% 
FCS, 2mM L-glutamine, 100 units/ml penicillin, 100 ?g/mL streptomycin, nonessential 
amino acids, 0.5 mM sodium pyruvate, 1 mM oxaloacetic acid, and 0.2 units/ml insulin.  
MEF cells (I) 
Mouse embryonal fibroblasts were derived from E15 and E17 wild type (wt) and EGF-R null 
mice  embryos.  Cells  were  cultured  in  DMEM  supplemented  with  10%  FCS,  2  mM  L-
glutamine, 100 units/ml penicillin, and 100 ?g/mL streptomycin. 
PC-3 cells (III) 
PC-3 (CRL-1435, prostate adenocarcinoma cell-line) was purchased from the ATCC and 
cultured in Hank´s F-12 medium supplemented with 7% FCS, 2mM L-glutamine, 100 
units/ml penicillin, and 100 ?g/mL streptomycin. 
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Inhibitor treatments (I,II,III) 
EGF-R-inhibitor ZD1839 (10 µM; AstraZeneca, London, UK), Mek-inhibitor PD98059 (20 
µM; Calbiochem, San Diego, CA), JNK-inhibitor SP (20 µM; Calbiochem), SB (20 µM; 
Calbiochem), PI3 K-inhibitor LY294002 (25 µM; Calbiochem), and COX-inhibitor Ind (50 
µM; Dumex-Alpharma, Copenhagen, Denmark) were added to the cultures 1 h before 
additional treatments including serum, EGF, PGE2, and TPA.  
6.2.2 Expression analyses 
Adenovirus infection (I) 
Wild type or EGF-R null MEFs were cultured on 100-mm diameter plates in DMEM 
containing 1% FBS and infected with recombinant adenoviruses for dominant negative c-Jun 
[AdTAM67 (300)] or catalytically active MEK1 [AdMEK1ca (299)] in a total volume of 3 ml 
and at a multiplicity of infection of 1500 (virus/cell ratio). After overnight infection, the cells 
were washed with PBS and cultured in serum free DMEM for additional 6 h with or without 
20 ng/ml EGF. 
Transfections and reporter gene analysis (I,III) 
For transactivation studies in (I), duplicates of 60-mm diameter plates containing 50 000 cells 
were transfected with the luciferase reporter constructs for collagenase 1 and mutated 
collagenase 1 promoters [AP1+ Ets+; intact AP-1 and ETS-binding sites, and AP1- Ets+; 
mutated AP-1 site but functional Ets-binding site (301)] using the Fugene-6 reagent (Roche). 
After 18 h the cells were stimulated with 20 ng/ml EGF or 10 nM TPA for additional 6 h. The 
activity of collagenase reporter was normalized to the protein concentration. Luciferase assays 
were performed according to the manufacturer’s instructions (Promega). 
For transactivation studies in (III), duplicates of 60-mm diameter plates containing 50 000 
cells were transfected with the luciferase reporter constructs for AP-1 binding site TRE (TPA 
response element) using the Lipofectamine 2000 reagent (Invitrogen). The activity of 
collagenase reporter was normalized to the protein concentration. Luciferase assays were 
performed according to the manufacturer’s instructions (Promega). 
For transfections of siRNA oligonucleotides in (III), triplicates of 24-well plate wells 
containing 50 000 cells were transfected with Fra1, JunD (Dharmacon), c-Jun, and Fra2 
(Sigma-Proligo) siRNAs using the Lipofectamine 2000 reagent (Invitrogen). 
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6.2.3 RNA analyses 
Northern analysis (I) 
Total RNA was isolated from MEFs by the single step method using Trizol (Invitrogen). For 
Northern blot analysis, 10 ?g of RNA was separated on a 1% agarose-formaldehyde gel and 
transferred to nylon membrane (Hybond-N, Amersham). Filters were hybridized with [?-
32P]dCTP-labeled cDNAs coding for c-Jun (302), c-Fos (303), MMP-2 (304), MMP-3 (304), 
MMP-14 (305), and GAPDH (306) cDNAs. Hybridizations and washing conditions were 
performed according to the instructions of the manufacturer. 
Real time quantitative PCR (II) 
Total  RNA  was  converted  to  cDNA  using  SuperScript  First-Strand  Synthesis  System  
(Invitrogen, Carlsbad, CA) with random hexamers. Real-time PCR reactions were performed 
with the Gene Amp 5700 Sequence detection system (Applied Biosystems, Foster City, CA). 
Human 18S rRNA served as an endogenous control. Each sample was measured in triplicates, 
and data analyzed by the delta-delta method for comparing relative expression results (ratio, 
2–[[DELTA]CP sample – [DELTA]CP control]). 
6.2.4 Electrophoretic mobility shift assay (EMSA) 
The cells were harvested, centrifuged, and quick-frozen in liquid nitrogen. Cell pellets were 
homogenized in lysis buffer. Equal amounts of soluble protein were measured using BCA 
Protein Assay Kit (Pierce). 
To assay AP-1 DNA-binding activity, cell extracts were incubated for 20 min at room 
temperature in reaction buffer containing [?-32P]ATP-labeled oligonucleotide probe. Protein–
DNA complexes were resolved on a 4% non-denaturating polyacrylamide gel containing 0.5X 
TBE and visualized by autoradiography. 
6.2.5 Protein analyses 
Chromatin immunoprecipitation assay and PCR analysis (I) 
Chromatin immunoprecipitation (ChIP) was performed as previously described (307). Briefly, 
wild type MEFs were fixed with formaldehyde and sonicated. Lysates were preincubated with 
protein A Sepharose and subjected to immunoprecipitation overnight at +4?C with rabbit IgG 
or antibodies against c-Jun and c-Fos (Cell Signaling Technology and Santa Cruz, 
respectively). Precipitates were washed several times and eluated from beads with elution 
buffer. Crosslinking was reverted by adding NaCl and heating at +67?C for 4h. The samples 
were precipitated with ethanol overnight at -20?C. After centrifugation, DNA was suspended 
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to TE buffer, recovered using NucleoSpin Extract II purification system (Macherey-Nagel), 
and analysed for AP-1 promoter sequence in MMP-3 gene using PCR.  
PCR was performed on ChIP products for 30 cycles using DyNAzyme II polymerase 
(Finnzymes). Control reactions with mouse genomic DNA were always carried out along the 
immunoprecipitated samples. The following primers for MMP-3 gene fragment were used: (-
189/+97) 5´-TGCCCCAGTTTTCTCTTTTG-3 and 5´-CGGAAGACCCTTCATTTTCA-3´. 
The PCR products were fractionated on agarose gels, stained with ethidium bromide, and 
analysed using AlphaImagerTM 2200 Documentation and Analysis System (Alpha Innotech 
Corp.). 
Enzyme Linked Immuno-Sorbent Assay (ELISA) (II) 
PGE2 concentration in the conditioned culture medium was analyzed using enzyme 
immunoassay according to the manufacturer's protocol (Cayman Chemical Company, Ann 
Arbor, MI). 
Immunofluorescence staining (II) 
FHs74Int cells were fixed in 4% paraformaldehyde (PFA). EGF-R-phospho-specific 
antibodies (Biosource International, Camarillo, CA) and Texas-Red-conjugated secondary 
antibodies (Jackson Laboratories, Bar Harbor, ME) were used. Actin filaments were stained 
with TRITC-conjugated phalloidin (Sigma Chemical Co.). 
Immunohistochemistry (II) 
Paraffin-sections (5 µm) were deparaffinized. For antigen unmasking, the slides were 
microwaved in 10 mM citrate-buffer (for COX-2 detection) or Proteinase K (Ready-to-use 
Proteinase K; Dako Cytomation, Glostrup, Denmark) treated (for EGF-R detection). 
Immunostaining was performed with COX-2 or EGF-R antibodies (#sc-03; Santa Cruz 
Biochemicals) and biotinylated goat anti-rabbit immunoglobulins (Vector Laboratories, 
Burlingame, CA). Immunoreactivity was visualized by avidin-biotin peroxidase complex 
solution (Vectastain ABComplex, Vector Laboratories) and 3-amino-9-ethylcarbazole (Lab 
Vision Corp., Fremont, CA). Counterstaining was performed with Mayer's hemalum (Merck, 
Darmstadt, Germany). Nonimmune rabbit serum served as a negative control. 
Immunoprecipitation (II) 
Cells were lysed in RIPA lysis buffer. Supernatants were incubated with protein A Sepharose 
beads (Amersham, Little Chalfont, UK) and with appropriate antibodies for overnight at 4°C. 
After washing in RIPA buffer, the absorbed complexes were removed from the beads by 
heating it in SDS sample buffer and subjected to Western analysis. 
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In vitro kinase assay (I) 
Cells were washed with PBS and solubilized in lysis buffer. JNK was immunoprecipitated 
using polyclonal JNK antibody (Santa Cruz) for 1 h at 4°C. Immunocomplexes were coupled 
to protein-A-Sepharose beads for 1 h and washed several  times with dilution buffer.  Kinase 
reactions were performed in kinase buffer for 20 min at 30°C using GST-c-Jun protein (amino 
acids 5–105) as a substrate. The phosphorylated c-Jun proteins were analyzed on a 10% SDS-
PAGE and immunoblotting using an antibody against c-Jun phosphorylated on serine 73 (Cell 
Signaling Technology). 
Western analysis (I, II, III) 
Cells were lysed in SDS sample buffer and sonicated. An equal amount (50 µg/lane) of 
protein was separated in a 10% SDS-PAGE gel and transferred onto nitrocellulose membrane 
(Bio-Rad, Hercules, CA) by electroblotting. Immunoblotting was performed using specific 
primary antibodies, horseradish peroxidase–conjugated secondary antibodies (Jackson 
Laboratories) and enhanced chemiluminescence protocol (Super Signal, Pierce, Rockford, 
IL). 
6.2.6 Functional assays 
Collagen contraction assay (I)  
Collagen gels were prepared using Collagen Type 1 (BD Biosciences). Seven volumes of 
collagen were mixed with two volumes of five-fold concentrated DMEM and one volume of 
0.2M HEPES (pH7.4), and kept on ice. Cells were mixed gently into neutralized collagen 
solution before transferred into 24-well plates (50 000 cells/well). Collagen polymerization 
was initiated by incubating the plates at 37?C for 30 min. Gels were detached from the well 
walls and cell culture media containing 10% FBS and appropriate MAPK and EGF-R 
inhibitors were added into the wells. Contraction process was observed daily. The statistical 
significance of differences seen in contraction assays was analyzed using student’s t-test. All 
p-values were two tailed. 
FACS analysis (III) 
For apoptosis and cell cycle assays the cells were harvested onto hypotonic Propidium Iodine 
solution and analyzed using FACS (CellCalibur; Becton Dickinson, Bedford, MA) and 
CellQuest (Apoptosis) as well as ModFit (cell cycle) softwares. 
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Irridation and colony forming assay (III) 
Cells were counted, plated and cultured for two days, and transfected one day prior receiving 
a dose of 4 Gy [unit of absorbed dose (J/kg)] at the Department of Oncology, Helsinki 
University Hospital, Helsinki, Finland. The irradiation was performed with the Varian Clinac 
600C/D  linear  accelerator  (Varian  Medical  Systems  Inc.;  Palo  Alto,  CA)  using  a 6-MV 
photon beam. The dose rate was 4 Gy/min. 
For colony forming assay cells were counted six hours after irradiation and one thousand cells 
were plated on a 6-well plate. After eight days the cells were fixed with 2% PFA and stained 
with 20% crystal violet stain, washed, and colonies ?20 cells were counted under a 
microscope. 
Zymogram assay (I) 
Analyses for gelatinase activity was carried out as previously described (308). Conditioned 
cell culture media was applied to 10% PAGE gels containing 2mg/ml gelatin (Sigma) in non-
reducing 4x Laemmli sample buffer. After electrophoresis, the gels were rinsed in washing 
buffer and reaction buffer and incubated in reaction buffer overnight at +37°C. The gels were 
stained with Coomassie brilliant blue and destained with destaining solution. 
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7. RESULTS AND DISCUSSION 
7.1 EGF-R, MAPK, and AP-1 regulate MMP function in fibroblasts (I)  
EGF-R in fibroblasts 
The EGF-R growth factor receptor is implicated to be a regulator of many cellular events such 
as proliferation, migration, survival, and apoptosis. Activated EGF-R conducts these effects 
via downstream signaling pathways MAPK, PI3K, STAT, and PLC-PKC, which transmit the 
signal to the nucleus and activate transcription factors such as AP-1. The EGF-R signaling is 
essential for many cell types during development and its deregulation or overexpression 
might lead to uncontrolled growth and tumorigenesis (12). During development or 
tumorigenesis, stromal cells, such as EGF-R expressing fibroblasts, can influence surrounding 
cells  and  tissues  by  expressing  growth  factors  and  MMPs  which  alter  cell  proliferation,  
angiogenesis, migration, and invasion capacities (28, 93, 105, 309). In addition, EGF-R 
downstream effector AP-1, which has a role in regulating the above mentioned expression of 
growh factors and MMPs, is frequently overexpressed in various human tumors and cancer 
cells.  It  has  been  recently  shown that  AP-1  can  significantly  promote  growth,  motility,  and  
invasion of human pulmonary epithelial cells via activating MMPs and EGF-R (310). The 
connection between the expression of AP-1 subunits and EGF-R induction has been revealed 
also in fibroblasts (311). However, normally MMPs are required during development for 
tissue-remodelling events such as bone and vascular remodelling, as well as mammary 
development (284), but they are also required to maintain homeostasis in adult tissue and take 
part in wound healing and infection (286).  
In this study, we investigated the role of EGF-R signaling, culminating to the activated AP-1, 
during fibroblast proliferation and matrix remodeling. Wild type (wt) and EGF-R–/– mouse 
embryonal fibroblasts (MEFs) were used as experimental model.  
First, the cellular characteristics such as proliferation rate, saturation density, apoptosis, 
morphology, and stress fiber formation of both wt and EGF-R–/– MEFs were studied. Wt and 
EGF-R–/– MEFs  were  cultured  and  their  growth  properties  compared.  In  contrast  to  the  wt  
MEFs, the proliferation rates and saturation densities of the EGF-R–/– MEFs at early passage 
numbers were reduced. However, after spontaneous immortalization, which occured 
approximately at passage number ten, no significant differences in the proliferation rates 
between wt and EGF-R–/– fibroblasts were detected. Interestingly, c-Jun–/– MEFs had a similar 
proliferation defect and a prolonged crisis before spontaneous immortalization (261). In 
addition, the reduced proliferation potential of JNK1–/– MEFs is similar to c-Jun–/– MEFs 
showing that the JNK1 also regulates fibroblast proliferation (312). To conclude, EGF-R and 
its downstream signaling pathways were involved in proliferation events in fibroblasts. 
However, EGF-R–/– fibroblasts showed no differences in other cellular characterstics such as 
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saturation density, apoptosis, morphology or stress fiber formation as compared with their wt 
counterparts. 
EGF-R and MMP interplay in fibroblasts    
The role of EGF-R in regulating MMP transcription and activity during cancer progression is 
well established (313, 314). However, the data on the role of EGF-R in fibroblasts during 
ECM remodelling is scarce. It is known that fibroblasts are involved in ECM remodelling 
such as wound contraction, which is a fundamental event in wound healing. Interestingly, 
wound healing is impaired in mice with a targeted deletion in the MMP-3 (stromelysin-1) 
gene (100). 
Therefore, we tested whether EGF-R depletion results in changes in ECM composition. 
Especially, we asked if the expression and activity of MMPs was impaired in EGF-R deficient 
fibroblasts.  
To analyze MMP activity in cell culture, we performed a collagen contraction assay, which 
mimics wound contraction in vitro. In this assay the ECM surrounding cells is composed of 
type I collagen and the reduction in gel diameter correlates to MMP activity (315). Although 
the contraction of collagen gels is known to induce collagenase (MMP-1) and stromelysin-1 
(MMP-3) activity (316), the ability of fibroblasts to contract collagen gels in vitro also 
depends on cytokines and cell adhesion receptors (such as integrins) interacting with type I 
collagen and laminin (317). 
The collagen contraction assay demonstrated a major difference in the contraction efficiency 
between wt  and  EGF-R–/– MEFs.  While  the  wt  MEFs contracted  the  gels  by  66% from the  
original diameter, the EGF-R–/– cells showed contraction of only 24%. Since this assay can be 
also used to study ECM reorganization in a simplified manner in wound healing, we 
performed additional experiments using EGF-R inhibitor. These analyses showed that EGF-R 
inhibitor significantly prevent contraction of wt MEFs. The data confirmed that collagen 
contraction of fibroblasts is primarily EGF-R-dependent. As MMP (pan)inhibitor Batimastat 
prevented collagen contraction of the wt MEFs, the results also indicate that the capacity of 
fibroblasts to contract collagen requires MMP activity.  
To further determine which MMPs or ECM molecules are abnormally expressed in EGF-R–/– 
MEFs, we compared RNA expression of wt and EGF-R–/– MEFs using ECM and adhesion 
pathways-focused microarrays. The EGF-R-deficient cells showed significant downregulation 
in the mRNA levels of several MMPs in comparison to wt cells. In particular, the expression 
of MMP-2, -11, -13, and -17 mRNAs was suppressed. However, other ECM molecules were 
also shown to be diffentially expressed between wt and EGF-R–/– MEFs. These included 
tissue inhibitor of metalloproteinases-1 (TIMP-1) and TIMP-2. Furthermore, the wt MEFs 
expressed MMP-2, -3, and -14 mRNA levels constitutively and the MMP-3 mRNA levels 
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were further increased using EGF stimulus in contrast to undetectable MMP-3 and low MMP-
2 and -14 mRNA levels in EGF-R–/– MEFs. 
The activity of MMP-2 was measured using a zymogram assay. As a result, MMP2 activity 
was found to be significantly reduced in the EGF-R–/– MEFs in comparison to wt MEFs. The 
finding correlates with the low MMP-2 mRNA expression. Basal MMP-9 expression levels 
and activities in turn were under detection limit in both cell lines. 
Our  data  show  that  EGF-R  plays  a  crucial  role  in  ECM  modulation  by  controlling  the  
expression  and  function  of  ECM  components  such  as  MMPs.  This  is  in  line  with  other  
studies. For example, matrix metalloproteinase driven EGF-R activation promotes human 
lung epithelial cell motility and invasion (318) and phenotype of ADAM–/– mice resembles 
that of EGF-R–/– mice (319). As ADAM17 is essential for the activation (ligand release) of 
EGF-R ligands in vivo, it may regulate autocrine signaling through the EGF-R creating a 
feedback mechanism (320).  
AP-1 regulates MMP expression in fibroblasts  
It has been shown that the activation of AP-1 plays an important role in TPA- and EGF-
induced tumor promotion in both in vitro and in vivo conditions (280). As the transcription 
factor AP-1 has also been characterized as a direct regulator of MMP expression, we studied 
whether AP-1 activity is regulated by EGF-R dependent mechanism. It is known that AP-1 
protein Fra-1 markedly stimulates MMP-2 and MMP-9 mRNA expression (318) but also 
other regulatory pathways such as NF?B (321), intracellular calcium (322), and nitric oxide 
(323) have been shown to regulate the expression of MMP-2 and MMP-9. 
To study basal and EGF-induced mRNA levels of c-jun and c-fos in wt and EGF-R–/– MEFs 
we used Northern blotting technique. Exposure of cells to EGF caused a rapid induction of c-
jun and c-fos mRNAs only in wt MEFs. Consistently, an induction of c-Fos and c-Jun protein 
levels was seen only in the wt MEFs. 
These  data  demonstrate  the  importance  of  EGF-R  in  the  regulation  of  AP-1  and  MMP  
expression. Since it is known that MAP kinase pathways have a role in EGF induced AP-1 
activation (240), we compared the activities of major pathways Erk1/2, Jnk1/2, and p38 in wt 
and EGF-R–/– MEFs. Our studies revealed that in wt MEFs, EGF rapidly phosphorylated 
EGF-R, Erks, and Jnks, whereas no p38 activity was detected. The kinetics of the activity of 
Erk and Jnk were consistent with the induction of MMP-3 expression. In contrast, induction 
of Erk and Jnk activities was impaired in response to EGF in the EGF-R–/– MEFs. Despite the 
differences in their  responses to EGF, both wt and EGF-R–/– MEF cells had similar TPA or 
UV responses indicating that the MAPK kinase activities in the EGF-R–/– MEFs are intact. 
Furthermore, no changes in the expression levels of Erk1/2, Jnk1/2, or p38 were detected in 
these cell types.  
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Previous studies of MAPK cascades have revealed that the Erk subgroup of MAP kinases is 
activated most potently by mitogenic stimuli, such as EGF, whereas Jnk and p38 kinases are 
activated  by  other  type  of  stimuli.  Therefore,  it  is  not  surprising  that  EGF-R–/– MEFs have 
impaired Erk activity but no other substancial kinase defects reflected in UV stimulus 
responses.  
EGF-R, MAPK, and AP-1 signaling regulate MMP expression and activity 
In order to study the role of Erk, Jnk, and p38 pathways in the EGF-R-dependent regulation 
of MMP expression in MEFs, we used specific kinase inhibitors to block basal or EGF 
stimulated kinase activity [ZD1839 (Iressa®) for EGF-R, PD98059 for Mek (upstream kinase 
of Erk), SB203580 for p38 and SP600125 for Jnk] and analyzed the expression of MMP-3, -
14, and -2 mRNAs with Northern blot technique. Again, when mRNA expressions of 
different  MMPs  were  analyzed  in  wt  and  EGF-R–/– MEFs,  striking  differences  were  
discovered between these cell lines. In wt MEFs, MMP-3 mRNA expression was 
downregulated in EGF-R inhibitor treated cells with or without EGF. EGF-induction of 
MMPs was mediated through Erk pathway, whereas Jnk inhibitor could only suppress the 
basal  MMP-3  mRNA  levels.  Basal  MMP-14  expression  was  dependent  on  EGF-R  and  Erk  
signaling, but p38 kinase inhibitor did not have any effect on the expression of MMPs. None 
of the inhibitors influenced the MMP-2 mRNA levels or MMP-2 activity. Basis for the 
impaired MMP-2 expression in the EGF-R–/– MEFs remain unclear. However, it is known that 
MMPs can activate each other by proteolysis. For example, MT1-MMP (MMP-14) has been 
shown to activate pro-MMP-2 and release the active MMP-2 in the extracellular space (324). 
This could be a plausible explanation to reduced MMP-2 activity detected in the zymogram 
assay. To summarize, the results show that the basal and inducible expression of MMP-3 and 
-14 are regulated by Erk- and Jnk-pathways, but the activities of these pathways or EGF-R are 
not required for the expression of MMP-2 in MEFs. 
Subsequently, we studied the involment of these pathways in modulating the ECM.  For this 
we used collagen contraction assay with the Erk, Jnk, and p38 inhibitors in order to study 
whether these inhibitors can prevent the collagen contraction of wt or EGF-R–/– MEFs. The 
addition of Mek and Jnk inhibitors resulted in partial inhibition of gel contraction, whereas 
p38 inhibitor did not have a major influence. However, this effect of Jnk inhibitor on gel 
contraction might partly result also from its negative affect on cell proliferation as this was 
observed in a proliferation assay. No suppression on proliferation of wt MEFs was observed 
with Erk inhibitor. Moreover, the MAPK inhibitors did not enhance the contraction defect in 
EGF-R–/– MEFs  but  Jnk  inhibitor  had  a  negative  effect  on  proliferation.  Together  with  the  
previous results obtained with EGF-R inhibitor, these results show that EGF-R-dependent 
activation of Erk pathway is required for collagen contraction in MEFs, whereas Jnk also 
regulates proliferation independently of EGF-R. 
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Next we analyzed the effect of EGF-R, Mek, p38, and Jnk inhibitors on the AP-1 subunits 
during  EGF stimulus  in  wt  MEFs.  In  line  with  previous  data  showing that  c-Jun  and  c-Fos  
expression was downregulated in EGF-R–/– MEFs, EGF-R inhibitor prevented the induction 
of both c-jun and c-fos mRNA levels in response to EGF in wt MEFs. In addition, the Mek 
inhibitor decreased c-fos, but not c-jun, mRNA levels, whereas p38 and Jnk inhibitors did not 
have an effect. This type of Erk regulated c-Fos expression has been previously reported to be 
mediated by Elk-1 (242). However, the downregulation of AP-1 mRNA levels is not reflected 
at the protein level directly because also posttranscriptional and posttranslational 
modifications can regulate AP-1 expression (228, 236). The most important posttranslational 
modification, which increases protein stability of c-Jun or c-Fos, is JNK or Erk mediated 
phosphorylation. In detail, the Erks phosphorylate c-Fos serines 362 and 374 (234) and JNKs 
or Erks phosphorylate c-Jun serines 63 and 73 (133, 239). Indeed, when the protein levels 
were studied, both Mek and Jnk inhibitors decreased c-Jun protein levels as well as 
phosphorylation (Ser73), suggesting that c-Jun protein stability requires both Erk and Jnk 
activities. Interestingly, p38 kinase inhibitor did not inhibit but rather stimulated the 
expression of c-Fos and c-Jun. This might result from a compensating effect by Jnk pathway, 
because p38–/– MEFs are reported to show upregulation of the JNK-c-Jun pathway (148). 
To further analyze the significance of AP-1 in regulating EGF-R-dependent (325) MMP 
expression in MEFs, we infected MEFs with an adenovirus construct producing TAM67, 
which a truncated, transactivation deficient form of c-Jun resulting in defective AP-1 activity. 
The expression of MMP-3 mRNA levels in the TAM67-infected wt MEFs showed a major 
supperession compared to control MEFs. Similar suppression was detected after EGF 
treatment. Moreover, we also analyzed the role of Mek/Erk in regulating MMP-3 expression 
using an adenovirus construct producing constitutively activated Mek infected into EGF-R–/– 
MEFs. This resulted in upregulation of MMP-3 expression in EGF-R–/– MEFs; however the 
expression level was still lower compared to wt MEFs. This is in line with with previous data 
showing that activated Mek1 stimulates MMP-3 expression in fibroblasts (325). 
In summary, this study shows that EGF-R signaling is involved in regulating proliferation and 
MMP expression in MEFs and that the effect is mediated by MAPK and AP-1 activities. The 
results support previous studies related to MMP mediated ECM modulation during 
development, highlighting the importance of stromal derived EGF-R signaling (93). Indeed, 
our result show that the expression of distinct MMPs is dependent on EGF-R signaling but 
interstingly also proliferation shows EGF-R dependence, as the proliferation defect of MEFs 
at early passages suggests. However this proliferation defect can be compensated by other 
mechanisms at later passages, resulting in EGF-R independent growth. Similar results have 
been acquired in an in vivo study using EGF-R–/– mice in a wound healing assay (326). This 
demonstrates that EGF-R is required in both important steps in wound healing; proliferation 
of epithelial keratinocytes in addition to would contraction mediated by MMP activities, 
which indicate stromal-epithelial interaction. Furthermore, the expression of many MMPs 
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involved in ECM remodelling is AP-1 regulated suggesting that AP-1 has a functional role in 
this process [reviewed in (327)]. In our studies EGF-induced and AP-1 regulated MMP-3 
showed to be an important regulator of collagen contraction. Consistent with this, MMP-3–/– 
MEFs show impaired collagen contraction (315) suggesting a connection between EGF-R 
signaling and MMP expression in fibroblasts.  
To elucidate the potential effects of EGF-R activation in MEFs, we illustrated the 
consequential signaling events in Figure 7. In this figure, based on our data, EGF activates 
particularly Erk kinases but also Jnk kinases in wt MEFs, resulting in transcriptional 
activation of AP-1 and increased proliferation of MEFs and MMP upregulation. MMP 
expression correlates to AP-1 activity and, furthermore, the expression and activity of specific 
MMPs lead to collagen contraction. The lack of EGF-R in MEFs manifests itself also in 
reduced basal expression and activity levels of MMPs in addition to decreased rate of 
proliferation. 
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Figure 7. Diagram of proposed signaling mechanisms in MEFs. 
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7.2 Hydrocortisone and indomethacin negatively modulate EGF-R signaling in human 
fetal intestine (II) 
EGF-R signaling in FHs74Int cells 
EGF-R and its ligands are important for the maturation of the embryonic gut and also 
postnatally in maintaining mucosal integrity (39, 328-330). Also hydrocortisone (HC) has 
been shown to accelerate maturation of the intestinal tract, mainly the appearance of the 
brush-border membrane hydrolases and lipoprotein synthesis (331-333). On the otherhand, 
concomitant use of HC and indomethasine (Ind) on very-birth weight infants has been 
associated with increased risk of intestinal perforations (334-336). Since the mechanisms 
behind this adverse event are unknown, we asked whether they could include modulation of 
EGF-R signaling. 
As a model system we used an immortalized, EGF-R expressing fetal intestinal cell line 
FHs74Int and various different kinase specific inhibitors. First, we analysed the patterns of 
EGF-R  signaling  in  FHs74Int  cells  treated  with  EGF.  Stimulation  with  EGF  led  to  the  
activation of EGF-R, Erk, and Akt kinases as expected and the specific EGF-R inhibitor 
ZD1839 blocked EGF-R phosphorylation and down-regulated both the MEK and PI-3 kinase 
signaling pathways to basal levels. Jnk and p38 pathways were not affected by EGF.  
Enterocyte proliferation 
Next we  sought  to  analyse  the  effects  of  EGF  and  HC  on  fetal  enterocyte  proliferation.  In  
addition, the effects of Ind and prostaglandin PGE2 were studied; Ind is a nonspecific 
inhibitor of COX, which catalyses the production of prostaglandin PGE2. Following nine days 
of  culture,  the  number  of  cells,  treated  with  EGF,  HC,  PGE2 or  Ind,  was  calculated.  EGF  
increased cell number by 80% in contrast to HC, Ind, or PGE2, which had no significant 
impact on proliferation. EGF-induced cell proliferation was prevented by kinase specific 
inhibitors for EGF-R (ZD1839), Mek (PD98059), and Jnk (SP600125). We also analysed the 
effects of combination treatments. Interestingly, when HC was used with EGF, cell 
proliferation was increased by 162 ± 17% (d 9). This synergistic effect was blocked using 
ZD1839. Similar observation has been reported also previously suggesting that the 
proliferative effect of HC is based on increased expression of Erk (337) or membrane 
receptors and enhanced EGF-EGF-R binding [reviewed in (338)] leading to modified EGF-
induction. However, HC alone or in combination with EGF had no affect on EGF-R, Erk, or 
Akt activities in the FHs74Int cells. Furthermore, we also analyzed whether the cell cycle 
regulators p21 and cyclin D1 were behind the proliferative synergism between EGF and HC. 
However, only EGF stimulus led to up-regulation of both p21 and cyclin D1 expression. This 
was in line with previous studies, in which activation of Erk is needed for the expression of 
cyclin D1 and p21 leading to cell cycle re-entry in CCL39 fibroblasts (339) or enterocytes 
(340).  
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In addition, our analysis comparing apoptosis between treated (EGF, PGE2, HC or Ind) or 
untreated cells revealed distinct differences in the level of apoptosis only in the cells treated 
with the high concentration of Ind (100 µM). 
Our results demonstrated that EGF signaling was important for the proliferation of intestinal 
epithelial  cells.  A  similar  result  was  obtained  in  a  recent  study  in  which  another  EGF-R  
specific inhibitor AG1478 significantly reduced the proliferation of cells within the epithelial 
cell layer of cultured gut explants (341). Indeed, this type of novel in vivo 3D models of the 
intestine  are  very  useful  to  study  the  roles  of  EGF-R  signaling  and  PGE2 because the 
homeostasis of proliferation and apoptosis is created by interaction between different cell-
types in the epithelium and stroma (77, 342). This is reflected by the known difficulties in 
intestinal epithelial cell growth and differentiation in in vitro models (343). 
EGF-R signaling and COX-2 interplay in vivo 
It is known that EGF-R signaling and cyclo-oxygenase-2 (COX-2)  have  also  roles  in  the 
development and progression of intestinal polyps and cancers. Direct cross-talk between these 
signaling pathways has been reported: in LS-174T colorectal carcinoma cells PGE2 induces 
the transactivation of EGF-R via Src kinase with a subsequent increase in migration and 
invasion (344). Furthermore, EGF enhances the expression of COX-2 in tracheal cell line 
EGV6 (345). 
Therefore, we studied whether EGF-R and COX-2 co-localize also in the fetal intestine in 
vivo. To study this, we immunostained human fetal intestine with COX-2 or EGF-R 
antibodies. A strong COX-2 immunoreactivity was detected in the crypts in duodenum and 
jejunum and also weakly in ileum. Similar results were obtained from EGF-R 
immunostaining. To further analyze the EGF-R and COX-2 interplay, we compared EGF-R 
and COX-2 immunostaining between EGF-R–/– and wt mice fetal intestines because EGF-R–/– 
mice have similar perforations in their intestine as the indomethasine treated infants (39). 
Interestingly, COX-2 expression was mainly detected in the crypts of the wt mouse jejunum 
similar to the location of immunoreactive EGF-R. In contrast, COX-2 expression was greatly 
reduced in the EGF-R–/– mouse jejunum. These results were confirmed by Western blot 
analysis. According the analysis, EGF-R–/– fetal intestine contained less COX-2 protein than 
the wt intestine. 
EGF-R signaling and COX-2 interplay in vitro  
Next we studied by qt-PCR whether EGF upregulated COX-2 levels in FHs74Int cells and 
was this regulation mediated by the Erk and PI3K-Akt pathways. Indeed, EGF induced COX-
2 mRNA levels by 25- to 30-fold (p < 0.01) and this effect was inhibited by EGF-R, Erk, and 
PI3-K inhibitors but also by HC (p < 0.01), which alone had no significant effect on COX-2 
transcription.  
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These results were confirmed by ELISA, in which PGE2 amounts were measured from cell 
culture media. Indeed, EGF increased PGE2 production by 175% (p < 0.01) correlating with 
the increased COX-2 mRNA expression, and HC downregulated this by 40% (p < 0.05). Ind, 
EGF-R, MAPK, and PI3-K inhibitors suppressed the PGE2 production to baseline as could be 
expected from the mRNA data. 
Furthermore, even if PGE2 had  no  significant  effect  on  the  growth  of  the  FHsInt74  cells,  it  
induced the activation of EGF-R, Erk, and Akt, all of which were inhibited by ZD1839. This 
verifies that transactivation of EGF-R by PGE2 takes place also in human fetal intestine cells 
in vitro. These results suggest a dual role for EGF-R signaling in regulating COX-2 
expression and on the other hand, mediating the PGE2 stimulatory effect. 
The effect of EGF and HC on migration of FHs74Int cells 
Intestinal homeostasis is a balance between proliferation, apoptosis, and migration of 
enterocytes and defects in these events might lead to intestinal perforation. Several mitogenic 
stimuli have been reported to be involved in intestinal migration. These include PGE2 (344) as 
well as EGF-R ligands EGF (329) and TGF? (346). Therefore we analyzed their role in 
FHs74Int cell migration using a Transwell migration assay. Since HC and Ind have been 
clinically associated with intestinal perforations; also they were included in the assay. The 
stimulation  of  FHs74Int  cells  with  EGF,  HC,  and  PGE2 consistently (p < 0.05) increased 
migration. Furthermore, EGF and HC had a synergetic effect by doubling cell migration (p < 
0.05). However, this increase in migration was not due to proliferation, because of the short 
time-line of the migration assay (36h) compared with the proliferation assay (9 days). These 
migratory stimuli were completely abolished by ZD1839 (p < 0.05) but also a slight inhibition 
of 15% by Ind was measured (p < 0.05). The increase in migration by EGF also correlated to 
EGF-induced transformation of FHs74Int cells to a fibroblast-like appearance. Interestingly, 
also the phenotypic change was most significant when EGF was combined with HC. 
In  conclusion,  our  data  demonstrated  the  involvement  of  the  EGF-R  not  only  in  the  EGF-
induced but also in the PGE2-induced migration of fetal intestinal cells. Therefore, 
interrupting PGE2 production by the COX inhibitor, Indomethacine, might imbalance the 
functional role of EGF-R in the intestinal homeostasis which could lead to intestinal 
perforations.  
In  response  to  mucosal  injury,  enterocytes  migrate  from  the  crypts  to  villus  tip.  This  is  
followed by epithelial proliferation with new enterocytes arising from stem cells in the crypt 
region of the intestine. After intestinal damage, basolateral EGF-R becomes exposed to the 
luminal environment and may be accessed by endogenous luminal EGF-R ligands such as 
EGF (347). In fact, there are several cues that EGF-R signaling has a crucial role in regulating 
intestinal injury responses. Firstly, EGF-R null mice showed features of necrotizing 
enterocolitis (NEC) (39) and secondly, low salivary EGF levels have been shown to correlate 
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with the development of NEC (348). Furthermore, EGF is also needed for goblet cell 
proliferation (80), which protects the enterocytes from the luminal contact by secreting mucin. 
These results indicate a potential positive effect for EGF administration for preterm infants 
with the risk of intestinal perforations. Indeed, EGF has been shown to have a cytoprotective 
role in the intestine reducing apoptosis (79) and improving intestinal barrier function (80). In 
addition,  in  a  recent  prospective  trial,  recombinant  human  EGF  was  used  to  treat  neonates  
suffering from NEC with a positive proliferative effect (349). However, the potential side-
effects need to be dealt with i.e. overexpression of EGF has been reported to result in growth 
retardation (29) and, moreover, both EGF-R and its ligands have been associated with 
carcinogenesis. This is particularily true for carcinoma of the colon where also COX2 
overexpression has been reported (350). Indeed, a non-selective COX inhibitor used with an 
EGF-R inhibitor reduced polyp formation in APCMin/+ mice more effectively than either agent 
alone demonstrating EGF-R and COX-2 interplay (351).  
Another interesting observation was that the addition of HC with EGF had a potentiating 
effect on both proliferation and migration, which indicate that HC might operate using EGF-
regulated signaling pathways in FHs74Int cells. Similar observations have been made with 
ovarian epithelial cells (352, 353), skin fibroblasts, and keratinocytes (354). However, the 
effect of HC in cultured cells is not well defined. In preterm infants, however, glucocorticoids 
such as dexamethasone but not HC have also severe long-term side-effects affecting the brain 
and the heart (355). At the molecular level this difference might result from different affinities 
to mineralocorticoid receptor and glucocorticoid receptor as well as dexamethasone´s higher 
potency and longer duration of action. To conclude, both HC and Ind have capabilities to 
negatively interphere with the cellular behaviour of enterocytes in fetal intestine. Therefore, 
their concomitant admistration should always be critically evaluated.  
Finally, a more complete understanding of how these elaborate cellular processes during a 
given stimulus lead to a desired response is needed. The diagram in Figure 8 illustrates 
signaling events, such as Erk and Akt pathways, which according to our studies; regulate 
cellular events such as proliferation, migration, transformation, and apoptosis in enterocytes. 
In  addition,  they  regulate  COX-2  expression,  which  consiquentially  effects  PGE2 levels. 
PGE2 has also the ability to transactivate EGF-R. HC stimulus enhances EGF-induced 
proliferation, migration, and transformation via yet an unknown mechanism.  
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7.3 Transcription factor AP-1 promotes cell growth and radioresistance in PC-3 
prostate cancer cells (III) 
Prostate carcinoma (PC) cells in the advanced state of disease can proliferate in the absence of 
androgen. One possible cause for this could be the upregulation of EGF-R expression during 
tumor progression (205), which might compensate for the loss of androgen mediated 
proliferation. This induction of EGF-R expression might be mediated by JKTBP1, a novel 
nuclear ribonucleoprotein (356). There exist several levels of crosstalk between androgen and 
EGF-R in cancer cells, which could take place during different stages of PC: EGF can induce 
the activation of the androgen receptor (357), androgen can mediate EGF-R up-regulation 
(358), and androgen receptor can interact with the EGF-R (359), all of which are associated 
with the MAPK and/or PI3K activities. However, the data covering EGF-R mediated MAPK 
and PI3K signaling in advanced androgen-independent PC is scarce. Because only few 
effective  treatments  exist  for  this  stage  of  disease  and  the  treatment  efficacy  should  be  
improved, it is important to gather more information about the behaviour of PC and its 
dependence of EGF-R. 
Therefore, our purpose was to determine the roles of EGF-R downstream pathways, focusing 
on MAPK and PI3K-Akt signaling and transcription factor AP-1 in cell growth and radiation 
response. As an experimental model we used PC-3 androgen independent prostate cancer cell 
line. 
As indicated in earlier reports, EGF-R signaling pathways MAPK and PI3-K show increased 
activity in many cancers including PC, which affect cellular processes like growth and 
resistance to chemotherapy (360, 361). In addition, in advanced PC the tumor-suppressor 
gene PTEN that downregulates Akt activity (362) is frequently mutated and produce a non-
functional form of PTEN. Moreover, the oncogene ras has the capacity to transform the 
prostate cancer cells towards androgen independent growth (363), emphasizing the 
importance of these pathways in PC.  
In our studies the expression levels and activity (phosphorylation state) of EGF-R, MAPK, 
and PI3-K in PC-3 cells were assessed by immunoblot analysis. The results showed that the 
treatment of the cells with EGF-R specific inhibitor (ZD1839) not only abrogated baseline 
phosphorylation of EGF-R but also partially suppressed of Erk and Akt activities. MEK 
inhibitor (PD) in turn specifically suppressed Erk activity, whereas PI3K inhibitor (LY) not 
only fully prevented Akt phosphorylation but was also able to suppress EGF-R expression 
and phosphorylation, as well as Erk phosphorylation.  
It is known that high number of EGF-R is associated with decreased responses to radiation 
therapy. In addition, inhibition of EGF-R enhances the efficiency of radiation therapy in 
murine carcinomas expressing high levels of EGF-R (364). We, therefore, performed a 
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clonogenic survival assay for PC-3 cells by treating them with increasing doses of ionizing 
radiation (0, 2, 4, and 8 Gy) with or without a 12h-pretreatment with kinase specific 
inhibitors. The treatments with EGF-R or MEK inhibitors showed no impact on the survival 
of PC-3 cells when incubation times were short (6 hours). In contrast, PI3K inhibitor 
sensitized PC-3 cells to radiation in a dose dependent manner. When the long term effect of 
inhibitors was analyzed, EGF-R inhibitor resulted in 60% decrease in colony formation in 
nonradiated control cells. A decrease in cell proliferation in the presence of PI3K inhibitor 
was also observed.  
The  results  demonstrate  the  dependence  of  EGF-R  and  PI3-K  signaling  for  proliferation  of  
PC-3 cells. In addition, PI3K is involved in mediating resistance to radiation. In comparison, 
MEK/Erk activities were not essential for either cellular event. This is in line with in vivo 
studies done with prostate cancer xenografts, in which EGF-R inhibition caused a decrease in 
proliferation (365) but had no radiosensitizing effect (366). However, prostate cancer 
xenografts with high EGF-R expression were sensitized to radiation when dual EGF-
R/VEGF-R inhibitor, AEE788 was used (367). The radiation response appears to be cell 
specific, since inhibition of EGF-R in gliomas radiosensitizes cells to apoptosis (368). 
Cell cycle progression and apoptosis 
In order to analyze the role of EGF-R signaling in proliferation and radiation responses of PC-
3 cells, we next investigated the effect of radiation treatment on the cell cycle distribution and 
apoptosis.  In  the  study,  PI  staining  measuring  DNA  content  and  FACS  were  used.  The  
treatment of the cells with PI3K inhibitor without radiation led to increased amount of the 
cells in the G1 phase and a concomitant decrease of the cells in the G2 and S phases. EGF-R 
or MEK inhibitors did not affect cell cycle distribution. Radiation of PC-3 cells in turn 
resulted in a significant increase of the amount of cells in the G2 phase. Treatment with PI3K 
inhibitor in combination with radiation further enhanced this effect. 
The effect of kinase inhibitors and/or radiation on apoptotic rate of PC-3 cells was measured 
using Annexin V/PI staining. Treatments with EGF-R or PI3K inhibitors alone or in 
combination with radiation led to an increase in apoptosis. However, increased apoptosis after 
combination treatment was not synergistic. Radiation alone or the inhibition of MEK had no 
effect on apoptosis. 
These results together with clonogenic survival assay demostrate that PI3K-Akt pathway 
plays a critical  role in the radioresistance of PC-3 cells.  The molecular effect  of Akt on the 
cell cycle might be associated with Akt´s ability to inhibit cell cycle regulator p27Kip1 directly 
or to downregulate its expression (369). 
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AP-1 is regulated by EGF-R in PC-3 cells 
It has been shown that EGF-R can activate transcription factor AP-1 leading to the expression 
of AP-1 target genes followed by changes in cellular behaviour (311, 318). Therefore, we 
studied the roles of EGF-R mediated MAPK and PI3K cascades in PC-3 cells in order to 
pinpoint the contribution of each cascade in regulating AP-1. 
To study possible regulatory function of AP-1 in prostate cancer cell growth and 
radiosensitivity, we examined expression levels of AP-1 subunits in PC-3 cells using 
immunoblotting. The expression of three Jun (c-Jun, JunB, JunD) and three Fos (c-Fos, Fra1, 
Fra2) subunits were assessed after 24h treatment with inhibitors. After exposure of cells to 
EGF-R inhibitor, the expression of c-Jun, Fra-1, and Fra-2 was slighly decreased in 
comparison to nontreated control cells. MEK inhibitor suppressed c-Fos levels strongly and 
Fra-2 levels only sightly. PI3K inhibition in turn led to a decrease in the expression of all the 
other AP-1 subunits except JunB, indicating that PI3K pathway activity is critical for the 
expression  of  AP-1  subunits.  In  contrast,  the  regulatory  role  of  EGF-R and  MEK might  be  
less important.  
Next, we performed a gel mobility shift assay to assess the AP-1 DNA-binding activity of the 
PC-3 cells. In untreated cells, a high constitutive AP-1 DNA-binding activity was detected. 
The EGF-R and PI3K inhibitors suppressed AP-1 DNA binding activity, while the MEK 
inhibitor had only a slight attenuating effect on DNA-binding. We further investigated the 
composition of active AP-1 DNA-binding complex using antibody perturbation assay. Based 
on these experiments, the DNA-binding complex was found to compose of all Jun proteins, 
Fra-1 and Fra-2, whereas c-Fos, FosB, or ATF-2 were not detected in the DNA binding 
complex. 
To further study EGF-R, MAPK, and/or PI3K dependent regulation of AP-1, we examined 
the transactivation potential of AP-1 by quantifying AP-1 luciferase reporter activities in the 
inhibitor treated PC-3 cells. This analysis showed that all inhibitors were able to reduce the 
AP-1 promoter activity. Again, the most prominent inhibition was seen with the PI3K 
blockade. The results clearly demonstrate that a constitutively active AP-1 in PC-3 cells is 
composed of Fra-1, Fra-2, and JunD subunits and regulated by PI3K. 
AP-1 subunits Fra-1, Fra-2, and JunD are required for proliferation and resistance to 
radiation 
In  order  to  analyze  the  role  of  AP-1  in  PC-3  cell  proliferation  and  radiation  responses,  the  
expression  of  Fra-1,  Fra-2,  and  JunD  was  knocked  down  with  siRNAs.  The  cells  were  
transfected with c-jun, junD, fra-1, or fra-2 siRNAs and the suppression of corresponding 
protein expression was analyzed by immunoblotting. SiCONTROL siRNA  served  as  a  
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negative control. The analysis verified a marked downregulation of the AP-1 subunits in 
comparison to PC-3 cells transfected only with the control siRNA. 
Next a colony forming assay was performed. Irridation (4Gy) of PC-3 cells led to 
approximately 25% cell survival. Downregulation of JunD, Fra1, or Fra2 expression with 
siRNAs sensitized PC-3 cells to irradiation by reducing the colony formation to 36%, 58%, 
and 78%, respectively, as compared to siCONTROL and c-jun siRNAs. Combination of c-jun 
siRNA with fra-1 or fra-2 siRNAs did not further enhance this effect, in comparison to each 
siRNAs alone. In contrast, combination of junD siRNA with fra-1 or fra-2 siRNAs resulted in 
a greater reduction in colony formation than either siRNA alone. These results clearly imply 
that JunD, Fra-1, and Fra-2 are needed for the survival of PC-3 cells. 
The proliferation rate of PC-3 cells was also reduced after the suppression of JunD, Fra-1, and 
Fra-2 expression. In contrast, suppression of c-Jun had no significant effect on the 
proliferation in comparison to control cells. Therefore, these results together with our 
previous studies indicate that JunD, Fra-1, and Fra-2 are essential for both the radioresistance 
and proliferation of PC-3 cells.  
We also determined the effect of a downregulation of AP-1 subunit on the cell-cycle 
distribution. The suppression of JunD, Fra-1, and Fra-2 by siRNAs alone or the combination 
of junD with fra-1 or fra-2 siRNAs led to the increased fraction of cells in G2 phase in 
comparison to cells transfected with siCONTROL and c-jun siRNAs. The results demonstrate 
that JunD, Fra-1, and Fra-2, but not c-Jun mediate radioresistance of the PC-3 cells.  
Notably AP-1 has a unique role in prostate cancer, since it is a downstream effector of EGF-R 
and it can also regulate transcriptional activity of the androgen receptor (370). Indeed, in a 
recent in vivo study using Nkx3.1;Pten mice and gene expression profiling, AP-1 transcription 
factor subunits c-Jun and c-Fos were demonstrated to be downstream effectors of EGF-R and 
MAPK signaling in cancer progression. Moreover, c-Jun subunit was associated with disease 
recurrence (282). C-Jun has also been indicated to have a definite role in androgen-
independent prostate cancer development (371). 
In other respects, this type of the use of gene expression profiling has not only provided new 
insights into prostate cancer, but has also confirmed and deepened the knowledge of the 
known signaling mechanisms, such as the function of AP-1 in prostate cancer. Nonetheless, it 
must be kept in mind that the cell context and microenviroment signaling might also influence 
AP-1 subunit expression [reviewed in (372)]. This should to take into consideration when the 
in vivo and in vitro studies are interpreted. 
In summary, our in vitro study provides cues to the role of AP-1 and its upstream effectors in 
growth and radiationresponse of PC-3 prostate cancer cells. The results suggest that the 
inhibitors of particular AP-1 subunits or Akt may be useful in designing new treatments 
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against advanced prostate cancer. Also EGF-R inhibition is advantageous if the expression 
levels are high, as might be the case in the metastatic stage of PC. In addition, the assessment 
of EGFR downstream signaling, such as the PTEN and Ras functionality, should also be 
considered. 
In Figure 9 we summarize both the upstream signals that modulate AP-1 activity and the AP-
1 components that mediate specific cellular resposes. EGF-induced EGF-R activation leads to 
Erk and Akt pathway activation, which are involved in regulating AP-1 expression and 
activity. Particularly Akt activity has a dramatic effect on proliferation, cell-cycle progression, 
and survival of PC-3 cells. AP-1 components JunD, Fra1, and Fra2 are the main downstream 
effectors of Erk and Akt pathways in PC-3 cells and their downregulation leads to 
sensitization of cells to irradiation, reduced proliferation, and changes in cell-cycle 
distribution. 
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8. CONCLUDING REMARKS 
The  role  of  the  EGF-R  as  a  relay  station  between  various  inputs  from  the  environment,  
cellular responses and other RTKs underlines the significance of this signal-transducing 
receptor. The inputs are relayed by specific messengers, the kinase pathways, to the nucleus, 
where the signal activates transcription factors leading to a change in a transcription of a 
desired target gene. The end product of this activity is therefore a specific protein, which 
carries out the desired cellular response. 
There is substancial amount of evidence that the EGF-R regulated pathways are essential in 
normal cellular responses like proliferation, apoptosis and migration during development and 
adult life. However, when these pathways are deregulated they contribute to abnormal growth 
and tumorigenesis by accelerating proliferation, inhibiting apoptosis, sustaining angiogenesis, 
and invasion.  
Our studies investigated the interplay between EGF-R network and AP-1 transcription factor. 
As a model system we used cell cultures of mouse embryonal fibroblasts (MEFs), human fetal 
enterocytes (FHs74Int) and human hormone-refractory prostate cancer cells (PC-3). They 
provided a mesenchymal, an epithelial and a malignant cell niche that partially differed in 
their response to the active EGF-R and AP-1 pathways. This resulted in changes in ECM 
remodelling, intestinal maturation, and resistance against radiotherapy.  
The main conlusions made from these studies were: 
1. Mesenchymal cells (fibroblasts) show coordinated EGF-R and AP-1 dependence in MMP 
expression and cell proliferation. Interestingly, Erk- and Jnk-pathways are required not only 
for EGF-induced expression but also for basal expression of MMP-3 and -14, which are AP-1 
target genes.  
2. Intestinal epithelial cells show EGF-R dependence in cell proliferation and an EGF-HC 
synergistic effect. COX inhibition by Ind also results in negative impact on enterocyte 
proliferation.   
3. Prostate cancer cells are dependent on Akt pathway and AP-1 subunits JunD, Fra1, and 
Fra2 in their resistance against radiotherapy. EGF-R in turn is mainly required for cell 
proliferation.  
Although, these cells express different levels of EGF-R on their surfaces, striking importance 
of this RTK is revealed. The results help us to understand the mechanisms of EGF-R and AP-
1 signaling. In general, the proteins studied here are kinases or transcription factors, which 
function by activating other proteins or regulating gene transcription. The cellular outcome is 
dependent on this complicated network of the pathways, which converge at the transciption 
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factors. This should be considered in the design of future cancer therapies since deregulated 
activation of numerous signaling pathways is a key element of cancer. Therefore, this study 
along with those of others is beginning to define a new rational combinational inhibitor 
treatment strategy for cancer. 
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